Methods and compositions for identifying and characterizing hepatitis C

ABSTRACT

The invention provides novel methods and compositions for amplifying portions of the HCV genome. The nucleic acid sequences set forth as SEQ ID NOS:1-64 derived from HCV cDNA and functional equivalents thereof, kits containing same, and methods employing same, are useful for the identification and characterization of HCV in biological samples.

RELATED APPLICATIONS

The present application claims priority to PCT Application No. PCT/US03/07585 filed on Mar. 11, 2003 which claims priority to U.S. Provisional Application Ser. No. 60/363603 filed on Mar. 11, 2002, which is herein incorporated by reference.

BACKGROUND OF THE INVENTION

The Hepatitis C virus (HCV) is the major etiologic agent for non-A, non-B hepatitis. It is estimated that around 400 million people or >2% of the world's population are infected (Di Bisceglie, A. M. (1998) Hepatitis C. Lancet 351:351-5; Houghton M. (1996), p. 1035-1058. In B. N. Fields and D. M. Knipe and H. P. M. (ed.), Fields' Virology, 3rd ed. Lippincott-Raven, Philadelphia/New York). HCV usually results in a chronic infection in 60 to 80% of infected individuals with 20% having progression to cirrhosis, hepatocellular carcinoma or chronic liver failure. At least 6 major viral genotypes and over 50 proposed subtypes of HCV have been identified worldwide (Simmonds, P. et al. (1994) Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 75:1053-1061).

These genotypes are based on nucleotide and amino acid sequence diversity with the most divergent isolates differing by more than 30% (Brechot, C. (1996) Hepatitis C virus: Molecular biology and genetic variability. Digestive Diseases and Sciences 41:6S-21S; Bukh, J. et al. (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41-63). Among the different types, there are regions which are highly conserved and have sequence homology close to 100%, however, in highly variable regions such as the envelope proteins homology is <70% (Booth, J. C. et al. (1998) Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27:223-27; Hayashi, N. et al. (1993) Molecular cloning and heterogeneity of the human hepatitis C virus (HCV) genome. J Hepatol 17:S94-107; Hijikata, M. et al. (1991) Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 175:220-228; Kato, N. et al. (1992) Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 22:107-123; Lesniewski, R. R. et al. (1993) Hypervariable 5′-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants. J Med Virol 40:150-156; Pozzetto, B. et al. (1996) Structure, genomic organization, replication and variability of hepatitis C virus. Nephrol Dial Transplant 11 [Suppl 4]:2-5; Vizmanos, J. L. et al. (1998) Degree and distribution of variability in the 5′ untranslated, E1, E2/NS1 and NS5 regions of the hepatitis C virus (HCV). J Viral Hepat 5:227-240).

HCV is a member of the Flaviviridae family whose other members include the Flaviviruses and Pestiviruses (Kato, N. et al. (1991) Molecular structure of the Japanese hepatitis C viral genome. FEBS Lett 280:325-328). The HCV genome is a positive-stranded RNA of ˜9.5 kb which contains a single open reading frame encoding a polyprotein of 3010 to 3033 amino acids (Takamizawa, A. et al. (1991) Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 65:1105-1113). Proteolytic processing of the polyprotein is accomplished by host and viral proteases. Host signal peptidases cleave the structural proteins which are located in the 5′ end, while two viral proteases cleave the non-structural proteins. These cleavages result in at least 10 viral proteins in the order NH₂-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. There are also non-coding regions located at the 5′ and 3′ ends which are involved in ribosome binding and replication initiation, respectively.

One of the viral proteases, the NS3 protease, is encoded by the N-terminal region of the HCV-NS3 gene. It consists of 181 amino acids and is a chymotrypsin-like serine-protease responsible for cleavage of the non-structural proteins of HCV (Bartenschlager, R. et al. (1993) Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 67:3835-3844; Eckart, M. R. et al. (1993) The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun 192:399-406; Gallinari, P. et al. (1998) Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 72:6758-6769; Hahm, B. et al. (1995) NS3-4A of hepatitis C virus is a chymotrypsin-like protease. J Virol 69:2534-2539; Hijikata, M. et al. (1993) Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 67:4665-4675; Hijikata, M. et al. (1993) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA. 90:10773-10777; Manabe, S. et al. (1994) Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3. Virology 198:636-644; Tomei, L. et al. (1993) NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67:4017-4026). Processing of the structural proteins by NS3 occurs in a well ordered cascade with the first cleavage occurring between NS3 and NS4A followed by NS5A-NS5B, NS4A-NS4B and NS4B-NS5A (Bartenschlager, R. et al. (1994) Kinetic and structural analysis of hepatitis C virus polyprotein processing. J Virol 68:5045-5055; D'Souza, E. D. et al. (1994) Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro. J Gen Virol 75:3469-3476; Eckart M. R., et al., 1993, supra; Failla, C. et al. (1994) Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 68:3753-3760; Kolykhalov, A. A. et al. (1994) Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol 68:7525-7533; Shimotohno, K. et al. (1995) Processing of the hepatitis C virus precursor protein. J Hepatol 22:87-92; Shoji, I. et al. 1999 Internal processing of hepatitis C virus NS3 protein. Virology 254:315-323; Tomei, L. et al., 1993, supra). The cleavage between NS3 and NS4A occurs in cis, while the other cleavages are in trans. The virus-encoded cofactor, NS4A is necessary for efficient NS3 fluction. Proteolytic processing efficiency has been shown to increase dramatically in the presence of the NS4A protein (Failla, C. et al. (1995) An amino-terminal domain of the hepatitis C virus NS3 proteinase is essential for the interaction with NS4A. J Virol 69:1769-1777; Failla, 1994, supra; Gallinari, P. et al. 1999 Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry 38:5620-5632; Lin, C. et al. (1995) A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol 69:4373-4380; Satoh, S. et al. (1995) The N-terminal region of hepatitis C virus nonstructural protein 3 (NS3) is essential for stable complex formation with NS4A. J Virol 69:4255-4260; Tanji, Y. et al. (1995) Hepatitis C virus-encoded nonstructural protein NS4A has versatile finctions in viral protein processing. J Virol 69:1575-1581). In addition, NS3 contains a tetrahedrally bound zinc atom, which appears to play a structural role (De Francesco, R. et al. (1996) A zinc binding site in viral serine proteinases. Biochemistry 35:13282-13287; Stempniak, M. et al. (1997) The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol 71:2881-2886).

Recently, considerable progress has been made in determining how the NS3 protease processes the HCV polypeptide (Kolykhalov, A. A. et al., 1994 supra; Steinkühler, C. et al. (1996) Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol 70:6694-6700; Urbani, A. et al. (1997) Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 272:9204-9209). Models for how the protease interacts with cofactors and the substrate have identified four domains, which are involved in enzyme function Barbato, G. et al. 1999. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289:371-384). These are the catalytic triad, cofactor and metal binding sites and the substrate-binding pocket. These domains are well defined and contain amino acid residues that are highly conserved in all HCV protease genes sequenced to date (See FIG. 1 in Holland-Staley, C. A., et al. (2002) Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 147:1385-1406, which is incorporated herein by reference). Despite this recent burst of structural information and studies showing direct involvement and conservation of amino acid residues, the impact of natural sequence variability on enzyme function is not well understood. In addition, the effects of anti-viral therapy on the NS3 protease sequence are unknown. Elucidation of the natural genetic diversity of the HCV NS3 protease in patient samples is of significant medical as well as theoretical interest. Though all HCV NS3 proteases sequenced to date contain conserved active-site amino acids, sequence variation throughout the NS3 gene is significant (Martell, M. et al. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes:quasispecies nature of HCV distribution. J Virol. 66:3225-32; Okamoto, H. et al. (1992) Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190:894-899; Okamoto, H. et al. (1992) supra). Also, the presence of multiple species within the same patient, known as quasispecies, creates a potential problem for drug development and resistance. Understanding the extent of NS3 sequence variation in clinical strains will allow more effective development of drugs targeting the HCV protease. For this, data must be available that describes sequence variability as it occurs in HCV-infected persons.

Helicases are enzymes that are responsible for unwinding DNA/DNA, RNA/DNA and RNA/RNA duplexes in a 3′-to-5′ direction. (Bartenschlager, R. et al., 1993, supra; Hahm B., et al., 1995, supra; Tomei, et al., 1993, supra). In addition, helicase enzymes have been proposed to play roles in viral replication and recombination, viral control of host cellular finctions, mRNA stability including splicing or processing, transcription, transport, and translation initiation of RNA (Lüking, et al. (1998) The protein family of RNA helicases. Crit. Rev. Biochem. Mol. Biol. 33:259-296). The HCV NS3 helicase/NTPase contains 450 amino acids. The NTPase component hydrolyzes nucleoside 5′-triphosphates, providing the energy requirements. The helicase/NTPase, along with the NS3 protease and NS5b RNA-dependent polymerase, are believed to make up a large complex, which is responsible for viral RNA replication. Recently, considerable progress has been made in determining the structure of the HCV NS3 helicase and its mechanism of duplex unwinding. At least three different crystal structures have been published (Paolini, Cho et al., 1998, supra; Kim et al., 1998, supra; and Yao et al. 1997, supra). In all three, the enzyme was shown to contain 3 domains, with domains 1 and 2 being structurally similar. The enzyme contains seven motifs, including two motifs which are involved in NTP-binding and hydrolysis (motif I [GxGKS] and motif II [DExH]) and one that is involved in ATP hydrolysis and RNA unwinding (motif VI). Most of the motifs are located between the structural domains 1 and 2, with domain 3 separated from the other two by the binding of the nucleotide. Investigators have identified highly conserved residues within each motif. These motifs, along with comparison analysis to other helicases, reveal it to be a member of the DEAD-box family of RNA helicases, specifically the DExH subfamily. Magnesium is required for both the helicase and NTPase activities.

The only FDA approved therapy for hepatitis C infection is interferon (IFN) or pegalated-interferon with or without ribaviron. Interferon production has been shown to be induced after infections with bacteria, parasites and viruses as well as in response to tumors. Interferons are secreted proteins in the cytokine family, which indirectly inhibit the viral life cycle by binding to cellular receptors, thus inducing protein synthesis (Hijikata, M. et al. (1993) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA. 90:10773-10777). Interferon inducible genes contain a promoter region, termed the IFN-stimulated response element (ISRE). Over 30 genes are induced by interferon, however, the function of most of these genes is unknown (Holmes, E. C. et al. (2000) The causes and consequences of genetic variation in dengue virus. Trends Microbiol 8:74-77).

Recently it has been suggested that a short stretch of 40 amino acids in the HCV NS5A gene play a role in IFN resistance, however, while this appears true for some Japanese isolates other investigators have conflicting data. The effects of interferon therapy on the other structural genes is unknown.

SUMMARY OF THE INVENTION

The present invention is based, at least in part, on the discovery of novel, isolated nucleic acid sequences for amplifying and sequencing portions of the HCV genome. The present invention provides novel sequences and methods of using same, which consistently amplify the HCV genome. The nucleic acid sequences of the present invention are useful as reagents for detecting and identifying viral sequences in biological samples and enable the further characterization of the HCV genome. The methods described herein, the nucleic acid sequences set forth as SEQ ID NOS:1-64 and functional equivalents thereof, as well as the kits containing them, are useful for accurately determining the presence of HCV in biological samples, as well as the specific sequence of a portion of the HCV genome. The nucleic acid sequences and methods of the present invention may be useful for: (i) detecting HCV infection, including early stage detection; (ii) identification of the type of HCV infection; (iii) detection of variant strains of HCV including heterogenicity in a patient; (iv) detection of a mutation in the HCV nucleic acid that is responsible for resistance or sensitivity to a therapy; (v) detection of new mutations in the HCV genome that are correlated with resistance or sensitivity to a drug therapy; (vi) determining whether treatment with an agent, e.g., an anti-viral agent, will be effective; (vii) determining whether treatment with an agent, e.g., an anti-viral agent, should or should not be continued; (viii) identification of the interaction between HCV and other viruses and/or diseases; (ix) generating a nucleic acid, e.g., DNA, vaccine, which may be patient specific; and (x) development of new drugs, e.g., based on x-ray crystallography.

The present invention features novel, isolated primer sequences from the HCV genome set forth herein as SEQ ID NOS:1-64 (Tables 1A-1G). Sequences which correspond to the HCV 1a and 1b subtypes are set forth as SEQ ID NOS:1-23 and SEQ ID NO:64 (Tables 1A and 1G); sequences which correspond to the HCV 2a subtype are set forth as SEQ ID NOS:24-27 (Table 1B); sequences which correspond to the HCV 2b subtype are set forth as SEQ ID NOS:28-42 (Table 1C); sequences which correspond to the HCV 3a subtype are set forth as SEQ ID NOS:43-46 (Table 1D); sequences which correspond to the HCV 3b subtype are set forth as SEQ ID NOS:47-50 (Table 1E); and sequences which correspond to the HCV 4a subtype are set forth as SEQ ID NOS:51-63 (Table 1F).

In one embodiment, the present invention features an oligonucleotide selected from the group consisting of SEQ ID NOS:1-64. In another embodiment, the oligonucleotides of the invention are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the nucleotide sequences set forth in SEQ ID NOS:1-64. In yet another embodiment, the oligonucleotides of SEQ ID NOS:1-64 are at least 4, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleotides in length. It will be appreciated that the 5′ end may contain greater variability (e.g., nucleic acid substitutions), yet remain finctional (e.g., able to anneal to the NS3 and NS4 portion of the HCV genome). In another embodiment, the invention provides a combination of one or more oligonucleotides of the present invention. In yet another embodiment, the invention provides a set of oligonucleotides, also referred to herein as “primers” and “nucleic acid primer sequences,” selected from the group consisting of two or more of the oligonucleotides of the present invention. In still another embodiment, the invention provides oligonucleotides which are able to amplify a patient sample having a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64, or complement thereof. In one aspect of the invention, the oligonucleotides of the present invention comprise a label for detection. Such labels may be, e.g., radioactive labels which may be incorporated by known methods (e.g., nick translation or kinasing), radioactive isotopes, biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), digoxigenin, enzymes, antibodies, luminescent agents, precipitating agents, dyes, combinations thereof, and the like. Another aspect of the invention comprises a vector comprising an oligonucleotide of the present invention.

In yet another embodiment, the invention provides an oligonucleotide for amplifying a nucleic acid sequence in a sample, wherein the sample contains a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64, or the complement thereof. In one aspect of the invention, the sample is from a patient infected with HCV.

In another embodiment, the invention provides a nucleic acid sequence, wherein the nucleic acid sequence is a promoter-primer comprising an oligonucleotide of the present invention, wherein a 5′ portion of the sequence includes a promoter sequence.

The amplified HCV nucleic acid sequences generated from the methods set forth herein may be cloned into a host vector with an expression promoter and used as a DNA vaccine to amplify a patient's response to the HCV virus, thereby providing a patient-specific DNA vaccine to HCV. In another aspect of the invention, the clone may be used to generate RNA for use as an antisense vaccine.

It will be appreciated that a sample used in the methods of the present invention may be a biological sample, e.g., from a patient infected with HCV. Such samples may include, without limitation, blood, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, urine, blood cells, tumors, organs, genomic DNA, RNA, or cDNA in solution or bound to a substrate, and also samples of in vitro cell culture constituents including, but not limited to, conditioned medium resulting from the growth of cells in cell culture medium, putatively virally infected cells, recombinant cells, and cell components, e.g., chromosome(s), organelles, paraffin embedded tissue, or membranes isolated from a cell.

In one embodiment of the invention, the serine protease portion of the HCV NS3 gene is analyzed. This can be accomplished by amplifying and sequencing the serine protease portion of the gene with the compositions and methods of the present invention. When a primer pair is employed as sequencing primers, either or both of the members of the pair may be suitably labeled, e.g., radioactive labels which may be incorporated by known methods (e.g., nick translation or kinasing), radioactive isotopes, biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), digoxigenin, enzymes, antibodies, luminescent agents, precipitating agents, dyes, combinations thereof, and the like.

In another embodiment of the invention, the helicase portion of the HCV NS3 gene is analyzed. This can be accomplished by amplifying and sequencing the helicase portion of the gene with the compositions and methods of the present invention. When a primer pair is employed as sequencing primers, either or both of the members of the pair may be suitably labeled, e.g., radioactive labels which may be incorporated by known methods (e.g., nick translation or kinasing), radioactive isotopes, biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), digoxigenin, enzymes, antibodies, luminescent agents, precipitating agents, dyes, combinations thereof, and the like.

Primer combinations, for example, including at least one forward and one reverse primer, which together can be used for amplification and/or sequencing of a relevant portion of the HCV genome, e.g., the NS3 or NS4 gene, may be suitably packaged in a kit. Nested pairs of amplification and sequencing primers are preferred. In one embodiment, the invention provides a kit for the detection of HCV, comprising one or more oligonucleotide of the present invention. In another embodiment, the kit comprises a set of primers selected from the group consisting of the oligonucleotides of the present invention. The primers in such kits may be labeled or unlabeled. The kit may also include additional reagents such as reagents for performing a polymerase chain reaction (PCR), a reverse transcriptase for conversion of the HCV RNA to cDNA for amplification, DNA polymerases, dNTP and ddNTP feedstocks. The kit may also include instructions for use.

The present invention also features novel methods for amplifying a target nucleic acid, e.g., specific regions of the HCV genome of a patient, such as NS3 and NS4 genes of the HCV genome, using the oligonucleotides of the present invention. The novel methods of the present invention may be used for, for example: (i) detecting HCV infection, including early stage detection; (ii) identification of the type of HCV infection; (iii) detection of variant strains of HCV including heterogenicity in a singe patient; (iv) detection of a mutation in the HCV nucleic acid that is responsible for resistance or sensitivity to a therapy; (v) detection of new mutations in the HCV genome that are correlated with resistance or sensitivity to a therapy; (vi) determining whether treatment with an agent, e.g., an anti-viral agent, will be effective; (vii) determining whether treatment with an agent, e.g., an anti-viral agent, should or should not be continued; (viii) identification of the interaction between HCV and other viruses and/or diseases; (ix) generating a nucleic acid, e.g., DNA, vaccine, which may be patient specific; and (x) development of new drugs, e.g., based on x-ray crystallography. This analysis may be performed by direct sequencing, or using other techniques for characterization of sequence polymorphisms, including but not limited to, hybridization with sequence-specific oligonucleotide probes.

Accordingly, in one embodiment, the invention provides methods for amplifying a target nucleic acid, e.g., portions of the NS3 or NS4 gene, by combining a target nucleic acid under conditions which allow for an amplification reaction to occur with one or more nucleic acid primer sequences of the present invention and other necessary amplification agents such as a nucleic acid polymerase and a plurality of nucleotides. In one aspect of the present invention, the amplification of a target nucleic acid sequence results in an increased amount of the amplified target nucleic acid. In yet another aspect of the invention, the target nucleic acid sequence is from the HCV genome, e.g., the NS3 or NS4A gene. In other aspects of the invention, the target nucleic acid is the serine protease portion of the NS3 gene. In still other aspects of the invention, the target nucleic acid is the helicase portion of the NS3 gene. In another aspect of the invention, a nucleic acid polymerase is used and may be selected from the group consisting of reverse transcriptase and thermostable DNA polymerase. In other embodiments of the invention, the amplified HCV nucleic acid is sequenced. In yet another aspect of the invention, the sequence is evaluated for mutations.

In another embodiment of the present invention, a method for detecting and characterizing HCV nucleic acids in a sample is provided by contacting the sample with one or more nucleic acid primer sequences of the present invention under conditions such that the HCV nucleic acids can hybridize with the primers of the invention, reverse transcribing and amplifying the nucleic acids to obtain amplified HCV nucleic acids, and detecting the presence of the amplified HCV nucleic acids. The amplified HCV nucleic acids may be fuirther characterized by, for example, sequencing the amplified nucleic acids. In one aspect of the invention, the detection of the presence of the amplified HCV nucleic acids comprises contacting the amplified HCV nucleic acids with a labeled oligonucleotide to obtain labeled HCV nucleic acids and identifying the labeled nucleic acids. In still other aspects of the invention, the amplification of the nucleic acids may be accomplished by nucleic acid sequence-based amplification (NASBA), Transcription Mediated Amplification (TMA), polymerase chain reaction (PCR), other target amplification methods, signal amplification methods or probe amplification methods such as Ligase chain reaction. In yet another aspect of the invention, the methods further comprise the step of sequencing the amplified HCV nucleic acids. In still another embodiment, the methods further comprise evaluating the sequence for mutations.

Once sequenced, mutations in the HCV genome may be identified by comparing the sequence with a known or a control sequence, e.g., a consensus sequence. Thus, the present invention provides compositions and methods for identifying particular mutations in the HCV genome. With the knowledge of a particular mutation in the HCV genome from a patient sample, appropriate therapy or combination therapy for the patient may be identified and administered. For example, the methods of the present invention may be used to determine a particular treatment regimen depending on the genotype of HCV that has infected the patient. In another embodiment, the invention provides compositions and methods for determining whether a patient is sensitive or resistant to an agent by obtaining a sample from a patient comprising DNA, performing amplification, e.g., PCR, on the DNA from the patient sample using a nucleic acid primer sequence of the present invention, and analyzing the amplified product, for example, by sequencing, to identify particular mutations. In still other aspects of the invention, the agent may be an antiviral agent, such as a protease inhibitor, an inhibitor of the serine protease portion of the NS3 gene, an inhibitor of the helicase portion of the NS3 gene, alpha-interferon, ribavirin, pegylated interferon, or a combination thereof.

Because the primer sequences of the present invention were derived from conserved regions of the HCV genome, the compositions and methods described herein will aid in the detection and/or identification of variant strains of HCV. This, in turn, will lead to the development of additional immunological agents for the detection and diagnosis of HCV, as well as the development of additional polynucleotide agents for the detection and or treatment of HCV.

In yet another embodiment, the invention provides a method for determining whether an agent can or can not be used to treat an HCV patient by obtaining a sample from a patient infected with HCV, amplifying the patient sample using the nucleic acid primer sequences of the present invention, sequencing the resulting amplified HCV nucleic acid sequences, and identifying mutations in the amplified HCV nucleic acid sequence that correlate with resistance or sensitivity to an agent, thereby determining whether the agent can or can not be used to treat an HCV patient. In one aspect of the invention, the nucleic acid sequences are a set of primers.

In another embodiment, the invention provides a method for determining whether treatment with an agent should be continued in a patient infected with HCV, the method comprising obtaining two or more samples comprising DNA from a patient during the course of treatment, amplifying and sequencing a target nucleic acid sequence from the sample using the nucleic acid primer sequences of the present invention in the methods described herein, identifying mutations present in the amplified nucleic acid sequence that correlate with resistance or sensitivity to an agent, and continuing treatment when the mutations identified in the amplified product do not change during the course of treatment.

In still another embodiment, the invention provides a method for determining whether treatment with an agent should not be continued in a patient infected with HCV, the method comprising obtaining two or more samples comprising DNA from a patient during the course of treatment, amplifying and sequencing the target nucleic acid sequences from the samples using the nucleic acid primer sequences of the present invention in the methods described herein, identifying mutations present in the amplified nucleic acid sequence that correlate with resistance or sensitivity to an agent, and discontinuing treatment when the mutations identified in the amplified product change, e.g., an increase in the number of mutations during the course of treatment is an indicator of resistance to an agent.

The Specific Examples set forth below also establish a correlation between HCV type, particularly as determined by analysis of the NS3 gene, and the likelihood that the virus will be responsive to anti-viral therapy, e.g., alpha-IFN therapy. Thus, a further aspect of the invention is a method for evaluating a patient diagnosed as or suspected of having an HCV infection to assess whether therapy, e.g., alpha-IFN therapy, is likely to be successful, comprising the steps of obtaining a sample from the patient containing DNA, comparing the serine protease portion of the NS3 gene and/or the helicase portion of the NS3 gene, to consensus subtype sequences, wherein the presence of one or more mutations is indicative of resistance to the therapy. It will be appreciated that this same methodology may be used to determine whether the virus (and thus the patient), will be sensitive or resistant to other anti-viral agents such as a protease inhibitor, an inhibitor of the serine protease portion of the NS3 gene, and an inhibitor of the helicase portion of the NS3 gene.

In another embodiment, the invention features a method of assessing the efficacy of an agent for treating HCV, the method comprising comparing nucleic acid sequences in a first sample obtained from a patient exposed to an agent, wherein the nucleic acid sequences are amplified products from one or more nucleic acid primer sequences of the present invention, and nucleic acid sequences in a second sample obtained from a patient who has not been exposed to an agent, wherein the nucleic acid sequences are amplified products from one or more nucleic acid primer sequences of the present invention, wherein an increased number of mutations in the nucleic acid sequences from the first sample, relative to the second sample, is an indication that the agent is not efficacious in treating HCV.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. (See e.g., Maniatis, Fitsch & Sambrook, Molecular Cloning; A Laboratory Manual (1982); DNA Cloning, Volumes I and II (D. N Glover ed. 1985); Oligonucleotide Sunthesis (M. J. Gait ed, 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); the series, Methods in Enzymology (Academic Press, Inc.), particularly Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively)). All patents, patent applications, and publications mentioned herein, both supra and infra, are hereby incorporated herein by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the results of a nested PCR reaction of Hepatitis C virus NS3 protease from 7 patient samples. The NS3 product is 2746 bp. The DNA MW ladder is in lane 1.

FIGS. 2A-2B depict phylogenetic trees constructed from 30 HCV NS3 protease strains using Parsimony Analysis and Neighbor-joining. FIG. 2A depicts a consensus tree of the parsimony analysis, while FIG. 2B depicts a bootstrap tree from the Neighbor-joining analysis.

DETAILED DESCRIPTION OF THE INVENTION

The term “agent” includes any known substance intended to treat an infection or disease, in particular, agents known to treat viral infections. The term “agent” is further intended to cover anti-viral agents including, but not limited to, a protease inhibitor, an inhibitor of the serine protease portion of the NS3 gene, an inhibitor of the helicase portion of the NS3 gene, alpha-interferon, ribavirin, and pegalated interferon.

The terms “amplification” or “amplify” include the reactions necessary to increase the number of copies of a nucleic acid sequence (e.g., a DNA sequence). For the purposes of this invention, amplification refers to the in vitro exponential increase in copy number of a target nucleic acid sequence, such as that mediated by a polymerase amplification reaction such as e.g., PCR, however, other amplification reactions encompassed by the invention include, e.g., RT-PCR (see, e.g., U.S. Pat. No. 4,683,202; Mullis et al.), and the ligase chain reaction (Barany, Proc. Natl. Acad. Sci. USA 88:189-193 (1991)).

The terms “Hepatitis C Virus” and “HCV” refer to the viral species that is the major etiological agent of BB-NANBH, the prototype isolate of which is identified in WO89/046699; EPO publication 318,216; and. U.S. Pat. No. 5,350,671, the disclosures of which are incorporated herein by reference. “HCV” as used herein includes the pathogenic strains capable of causing hepatitis C, and attenuated strains or defective interfering particles derived therefrom. The HCV genome is comprised of RNA. It is known that RNA-containing viruses have relatively high rates of spontaneous mutation, reportedly on the order of 10.sup.-3 to 10.sup.-4 per incorporated nucleotide (Fields & Knipe, “Fundamental Virology” (1986, Raven Press, N.Y.)). As heterogeneity and fluidity of genotype are inherent characteristics of RNA viruses, there will be multiple strains/isolates, which may be virulent or avirulent, within the HCV species.

The terms “hybridize” or “hybridization” are art-known and include the hydrogen bonding of complementary DNA and/or RNA sequences to form a duplex molecule.

The term “kit” is any manufacture (e.g., a package or container) comprising at least one reagent, e.g., a primer, for specifically amplifying and/or sequencing a portion of the HCV genome, the manufacture being promoted, distributed, or sold as a unit for performing the methods of the present invention. A kit may also include instructions for use.

The term “label” refers to a molecular moiety capable of detection including, by way of example, without limitation, radioactive labels which may be incorporated by known methods (e.g., nick translation or kinasing), radioactive isotopes, biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), digoxigenin, enzymes, antibodies, luminescent agents, precipitating agents, dyes, and the like.

The term “nucleotides” refers to any nucleotide (including modified nucleotides, e.g., methylated or biotinylated nucleotides) that can be incorporated into a nucleic acid by a polymerase.

As used herein the term “nucleic acid” includes DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), and analogs of the DNA or RNA generated using nucleotide analogs or using nucleic acid chemistry. Typical modifications include methylation, biotinylation, and other art-known modifications. In addition, the nucleic acid molecule can be single-stranded or double-stranded.

The term “target nucleic acid” or “template” includes any nucleic acid intended to be copied in, e.g., a polymerase amplification reaction such as PCR.

The term “probe” refers to a structure comprised of a polynucleotide that forms a hybrid structure with a target sequence, due to complementarity of at least one sequence in the probe with a sequence in the target region. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs. Included within probes are “capture probes,” “blocking probes,” and “label probes.”

The term “primer” or “nucleic acid primer” or “nucleic acid primer sequence” includes single-stranded oligonucleotides that, typically, are between about 4 to about 100 bases, or alternatively between about 17 to 30 bases, or alternatively 20 or more bases, and are designed to hybridize with a corresponding template nucleic acid. Primer molecules may be complementary to either the sense or the anti-sense strand of a template nucleic acid and are typically used as complementary pairs that flank a nucleic acid region of interest.

The term “polymerase” includes any one of, or a mixture of, the nucleotide polymerizing enzymes E. coli DNA polymerase I, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, reverse transcriptase where the template is RNA and the extension product is DNA, or a thermostable DNA polymerase. The term “thermostable DNA polymerase” includes a thermostable DNA polymerase isolated from Thermus aquaticus, Thermus thermophilus, Thermus filiformis, Thermus flavus, Pyrococcus furiosus, Thermococcus literolis, a Thermotoga species, or a recombinant form thereof.

The term “sample” or “biological sample” refers to a sample of tissue or fluid isolated from an individual, including but not limited to, blood, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, urine, blood cells, tumors, amniotic fluid, organs, genomic DNA, RNA, or cDNA in solution or bound to a substrate, and also samples of in vitro cell culture constituents including, but not limited to, conditioned medium resulting from the growth of cells in cell culture medium, putatively virally infected cells, recombinant cells, and cell components, e.g., chromosome(s), organelles, paraffin embedded tissues, or membranes isolated from a cell.

The “sense strand” of a nucleic acid contains the sequence that has sequence homology to that of mRNA. The “anti-sense strand” contains a sequence which is complementary to that of the “sense strand.”

The term “target region” refers to a region of the nucleic acid that is to be amplified and/or detected. The term “target sequence” refers to a sequence with which a probe or primer will form a stable hybrid under desired conditions.

The term “targeting polynucleotide sequence” as used herein, refers to a polynucleotide sequence which is comprised of nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarity with the target sequence to form a duplex which has sufficient stability for the purpose intended.

HCV has at least six genotypes, and multiple subtypes within each genotype. Sequences which correspond to the HCV 1a and 1b subtype may be selected from SEQ ID NOS:1-23 and SEQ ID NO:64, set forth in Tables 1A and 1G. Sequences which correspond to the HCV 2a subtype may be selected from SEQ ID NOS:24-27, set forth in Table 1B. Sequences which correspond to the HCV 2b subtype may be selected from SEQ ID NOS:28-42, set forth in Table 1C. Sequences which correspond to the HCV 3a subtype may be selected from SEQ ID NOS:43-46, set forth in Table 1D. Sequences which correspond to the HCV 3b subtype may be selected from SEQ ID NOS:47-50, set forth in Table 1E. Sequences which correspond to the HCV 4a subtype may be selected from SEQ ID NOS:51-63, set forth in Table 1F. The sequences of the invention, set forth as SEQ ID NOS:1-64, are defined in the Sequence Listing of the application.

In one embodiment, the oligonucleotides of the present invention are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the nucleotide sequence set forth in SEQ ID NOS:1-64. In yet another embodiment, the nucleic acid molecule of SEQ ID NOS:1-64 is at least 4, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleotides in length. It will be appreciated that the 5′ end may contain greater variability (e.g., nucleic acid substitutions), yet remain ftmctional (e.g., able to anneal to the NS3 and NS4 portion of the HCV genome).

The preparation of the nucleic acid sequences of the present invention is by means known in the art, including, for example, by methods which include excision, transcription, or chemical synthesis. The target sequences and/or regions of the genome which are selected to which the targeting nucleic acid sequence are complementary depend upon the purpose. For example, if the goal is to screen for the presence of HCV in biological samples (e.g., blood), the preferred nucleic acid sequence would be used as primers, and would hybridize to conserved regions of the HCV genome. Some of the conserved regions of the HCV genome to which the nucleic acid sequences of the present invention may bind are described herein. Other regions of the genome which are conserved are ascertainable by comparison of the nucleotide sequences of various isolates of HCV as described herein.

It will be appreciated that the nucleic acid sequences of the present invention need not consist only of the sequence which is complementary to the targeted HCV sequence. Thus, the nucleic acid sequences of the present invention may contain in addition, nucleotide sequences or other moieties which are suitable for the purposes for which the nucleic acid sequences are used. For example, use of the nucleic acid sequences as primers may be used for the amplification of HCV sequences via PCR, they may contain sequences which, when in duplex, form restriction enzyme sites which facilitate the cloning of the amplified sequences.

The nucleic acid sequences of the invention may be used as probes to detect the presence of HCV polynucleotides (for example in screening for contaminated blood), the biological sample to be analyzed, such as blood or serum, may be treated, if desired, to extract the nucleic acids contained therein. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample may be dot blotted without size separation. In order to form hybrid duplexes with the targeting sequence of the probe, the targeted region of the nucleic acid must be in single stranded form. Where the sequence is naturally present in single stranded form, denaturation will not be required. However, where the sequence is present in double stranded form, the sequence will be denatured. Denaturation can be carried out by various techniques known in the art. Subsequent to denaturation, the analyte nucleic acid and probe are incubated under conditions that promote stable hybrid formation of the target sequence in the probe with the putative targeted sequence in the analyte, and the resulting duplexes containing the probe(s) are detected.

Detection of the resulting duplex, if any, is usually accomplished by the use of labeled probes; alternatively, the probe may be unlabeled, but may be detectable by specific binding with a ligand which is labeled, either directly or indirectly. Suitable labels, and methods for labeling probes and ligands are known in the art, and include, for example, radioactive labels which may be incorporated by known methods (e.g., nick translation or kinasing), radioactive isotopes, biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), digoxigenin, enzymes, antibodies, luminescent agents, precipitating agents, dyes, and the like.

The amplified HCV nucleic acid sequences generated from the methods set forth herein may be cloned into a host vector with an expression promoter and used as a DNA vaccine to amplify a patient's response to the HCV virus, thereby providing a patient-specific DNA vaccine to HCV. In another embodiment, the clone may be used to generate RNA for use as an antisense vaccine. In one embodiment, an HCV vaccine is provided and employed as an immunotherapeutic agent for the prevention of HCV. In another embodiment, a HCV vaccine is provided and employed as an immunotherapeutic agent for the treatment of HCV.

By way of example, an HCV vaccine may be employed for the prevention and/or treatment of HCV in a subject by administering the vaccine by a variety of routes, e.g., intradermally, subcutaneously, or intramuscularly. In addition, the HCV vaccine can be administered together with adjuvants and/or immunomodulators to boost the activity of the vaccine and the subject's response. In one embodiment, devices and/or compositions containing the vaccine, suitable for sustained or intermittent release could be, implanted in the body or topically applied thereto for the relatively slow release of such materials into the body. The HCV vaccine can be introduced along with immunomodulatory compounds, which can alter the type of immune response produced in order to produce a response which will be more effective in eliminating the virus.

SPECIFIC EXAMPLES Example 1 Genetic Diversity and Response to Interferon of the NS3 Protease Gene from the Clinical Strains of the Hepatitis C Virus

This example describes an analysis of natural genetic diversity within the NS3 gene, wherein a nested PCR method was developed to obtain HCV NS3 sequence data directly from patient strains. The data was analyzed to determine overall genetic diversity, phylogeny of the virus, and selection of genetic variants by interferon therapy with or without ribavirin. The effects of genetic diversity on enzyme structure using molecular modeling were determined. Thus, a comprehensive approach was developed to facilitate analysis of natural genetic variation within this gene and its effects on protein structure.

The N-terminal one-third of the hepatitis C virus nonstructural gene 3 (NS3) codes for a serine protease (see FIG. 1 in Holland-Staley, C. A., et al., 2002, supra).

While genetic diversity has been shown to be extensive in other regions of the HCV genome such as the envelope region, the extent of diversity within the HCV NS3 protease region is largely unknown. Accordingly, the data set forth herein was used to determine the evolutionary rates of the virus and to identify the effects of mutations on enzyme structure. To investigate natural genetic diversity of this enzyme a nested PCR reaction was developed to obtain NS3 protease sequence data directly from patient strains. This data was used to determine genetic diversity, phylogenetic and evolutionary rates, and selection of variants by interferon therapy. The potential effect of genetic diversity on enzyme structure using molecular modeling was also attempted. In doing these experiments, a database of naturally occurring sequences has been established. This database is usefuil in the development of new antiviral therapy.

Genetic diversity among strains is important because of evidence that some HCV types are more pathogenic than others Cooreman, M. P. et al. (1996) Hepatitis C virus: biological and clinical consequences of genetic heterogeneity. Scand J Gastroenterol Suppl 218:106-115; Dusheiko, G. et al. (1994) Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19:13-18; Stempniak, M. et al. (1997) The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol 71:2881-2886), i.e., HCV type 1 over other types, and subtype 1b over subtype 1a. The cause for increased pathogenesis in these strains is unclear. Describing differences among strains that have a rapid progression to disease in comparison to those which don't, will help to elucidate the possible cause and mechanisms of pathogenesis (Farci, P. et al. (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344). Recently, Yanagi et al. (Yanagi, et al. (1998) Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244:161-172) showed that the number of mutations within the HCV genome can be directly related to infectivity. They chose three chimeric cDNA clones from the same source and inoculated chimpanzees. Of the three clones, only one was infective. This clone contained 3 amino acid substitutions when compared to the parent strain while the non-infective clones contained 7 and 9 amino acid substitutions. This may indicate a selection bias in chimpanzees due to immune system differences instead of an HCV strain characteristic (Bassett, S. E. et al. (1998) Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 72:2589-2599). In another study, when hypervariable region 1 was examined (Shindo, M. et al. T (1996) The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology 24:1018-1023) it was shown that higher amounts of heterogeneity were associated with a poorer overall response despite treatment with alpha-interferon. In addition, Chambers, T. J. et al. (Chambers, T. J. e al. (1991) Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 65:6042-6050); established that mutations which affected activity of the NS3 protease from the Yellow Fever virus, were lethal for viral replication. The outcome of these studies affirms the need to further characterize the role that heterogeneity plays in HCV infection. The compositions and methods of the present invention provide a mechanism for such characterization. Filocamo et al., 1999. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses. J Virol 73:561-575 used chimeric Sindbis viruses (SBV) to analyze variants of the NS3/NS4A protease, however, their study used a cloned protease and relied on the SBV replication machinery to produce sequence variation. While this allowed characterization of new protease variants, these variants may or may not represent those obtained from HCV replication in vivo. In addition, Forns et al. (Forns X., et al. (1997) How Escherichia coli can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure. Proc Natl Acad Sci USA 94:13909-13914) found when cloning PCR products of HCV structural proteins into E. coli, that a strong selection for defective clones occurred and accurate representation of true genetic diversity did not occur. The reason for this is unclear; however, toxicity to the E. coli host by viral proteins may play a role. Direct sequencing from patient samples should give a more accurate representation of true genetic diversity.

Most RNA viruses have a high mutation rate due to the lack of proofreading enzymes and because RNA-dependent RNA polymerases are thought to randomly produce one error per round of genomic replication (Drake, J. W. (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 90:4171-4175). Therefore, if there are 10⁷⁻⁸ viruses produced per day and the mutation rate is random, then each site will theoretically contain an equal number of mutations. The data set forth herein, however, showed that this was not the case, indicating that while the mutations were random, some regions of the virus are more permissive to mutations than other regions. This suggests that the virus, or at least the NS3 protease region, is subject to other functional constraints. The location of amino acid changes in the HCV NS3 protease from clinical strains indicates that amino acid substitutions take place in both the N- and C-terminal domains. It has already been demonstrated that the N-terminal domain of NS3 exhibits a structural plasticity upon NS4A binding. Kim, J. L. et al. (Kim, J. L. et al. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355) and; Yan, Y. et al. (Yan, Y. et al. (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7:837-847) reported that the N-terminal domain is flexible since the binding of the NS4A leads to ordering on the N-terminal 28 residues and causes local rearrangements for a catalytically more favorable conformation of the active site. Activation of the NS3 protease by the NS4A peptide leads to a ˜950-fold enhancement of catalytic hydrolysis of peptides mimicking the NS4A/NS4B junction (Yan. Y. et al. 1998 supra). Based on structural changes predicted from the sequences of clinical HCV strains, it is believed that there will be finctional changes relative to the wild type protease. An example of such a change would be the alteration of the pseudo-second-order rate constant (k_(cat)/K_(M)) for the various clinical strains. A second observation is that structural variation of HCV NS3/NS4A complex ought to be factored into the structure-based design of the inhibitors in order to retain efficacy against a wide range of clinical isolates.

For patient strains 23 and 25, the differences in subtype designation between the 5′ untranslated region and the NS3 protease region is unknown, but may occur due to the presence of more than one subtype. Simultaneous infection with multiple species of Dengue virus has been shown to occur (Gubler, D. J. et al. (1985) A case of natural concurrent human infection with two dengue viruses. Am J Trop Med Hyg 34:170-173). For HCV infection, this is most likely due to multiple blood transfuisions or infections through IVDA. Because HCV subtypes 1a and 1b are most predominant in this geographical distribution, the likelihood that they would recombine increases. Evidence of recombination has been shown in Dengue virus, where genetic diversity occurs when the RNA polymerase switches between two different genomes during replication, resulting in a hybrid RNA (Holmes, E. C. et al. (2000) The causes and consequences of genetic variation in dengue virus. Trends Microbiol 8:74-77). This may be the case with strains 23 and 25, where they typed as HCV1a based on the 5′ untranslated region, but closer to the HCV1b lade by the NS3 protease nucleotide sequence. The sequence results were clean, and did not show evidence of more than one species, suggesting recombination occurred prior to the start of NS3. Amino acid sequence comparison, however, showed very different results. Patient 23 had 3 mutations when compared to the type 1a consensus and 16 mutations when compared to the type 1b consensus. Patient 25 showed similar results with 4 mutations when compared to type 1a and 16 when compared to type 1b. The differences between nucleotide sequence analysis and protein analysis is unknown. Without being limited by theory, it is believed that these two strains represent a new subtype, which falls on the evolutionary tree between subtypes 1a and 1b.

This example revealed that there is significant variability in clinical HCV strains at both the nucleotide (30.2% for 1a and 25.8% for 1b) and amino acid sequences (12.2% for 1a and 12.2% for 1b). Phylogenic analysis showed two distinct clades with two HCV isolates grouping as a sister clade to 1b. Moreover, structural analysis revealed that most mutations lie in the N-terminus of the enzyme. When strains were sorted as to whether or not the patient had received antiviral therapy, no difference was found in the number or locations of mutations in la strains. However, 1b strains demonstrated an overall drop in the number of positions that were mutated. Thus, this study demonstrated that there are significant differences among natural strains that may pose a problem for structure-based drug development, for which this invention provides a solution.

The relationship between sequence variation and structural changes in the HCV NS3/NS4A complex can also be done by X-ray crystallography. Based on the compositions and methods of the present invention, anti-viral, including anti-HCV, drugs can be designed and developed with knowledge of the variability in the structure in the NS3/NS4A complex from HCV clinical strains to ultimately develop effective therapies against HCV.

Materials and Methods

Extraction of Viral RNA

HCV RNA was isolated from patient serum using the QIAamp viral RNA mini isolation kit (Qiagen Inc., Valencia, Calif.). Isolation was performed according to manufacturers directions.

RT-PCR and Amplification of Viral RNA

The Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) followed by a 2^(nd) round ‘nested’ PCR reaction was used to amplify the entire NS3 gene of HCV subtypes 1a or 1b, from clinical strains. For the RT-PCR step, the Promega Access Reverse Transcriptase PCR kit (Promega Corporation, Madison, Wis.) was used. For this, two oligonucleotide primers flanking the HCV NS3 gene were designed. The 5′ primer set forth in SEQ ID NO:1 anneals 881 bp before the start of the NS3 gene. The 3′ primer set forth in SEQ ID NO:2 anneals 338 bp downstream of NS3 and is used to initiate the RT step (Table 1G, SEQ ID NOS:1-4, SEQ ID NO:64 and SEQ ID NO:6, “Amplification” subsection). This allows cDNA production followed by initial amplification of the desired region. The amplification mixture containing 25 pmol of each primer, 200 μM dNTPs, 2.5 U AMV RT-polymerase, 2.5 U Tfl DNA polymerase, 1.5 mM MgSO₄, and 20 μl of viral RNA was added to a preheated (48° C.) Perkin-Elmer 9700 thermocycler (Perkin Elmer Cetus, Foster City, Calif.). The PCR protocol consisted of an RT step at 48° C. for 45 minutes, followed by an initial denaturation at 94° C. for 2 minutes, and 35 cycles of, 94° C. for 15 seconds; 55° C. for 20 seconds; 72° C. for 2 minutes; and a final extension at 72° C. for 10 minutes.

For the second step PCR reaction, the 1^(st) round PCR product was amplified using primers that anneal inside the previous reaction, creating a ‘nested’ amplification. The second round PCR reaction used the 5′ primer set forth as SEQ ID NO:3 which anneals 693 bp upstream of NS3 and the 3′ primer set forth as SEQ ID NO:4 which anneals 161 bp downstream. The amplification mixture containing 25 pmol of each primer, 200 μM dNTPs, 2.5 U Taq© DNA polymerase, 1.5 mM MgSO₄, and 5 μl of 1^(st)-round product was added to a preheated (94° C.) thermocycler. Initial denaturation consisted of 10 minutes at 94° C., followed by 35 cycles of, 94° C. for 15 seconds; 55° C. for 20 seconds; 72° C. for 2 minutes and a final extension at 72° C. for 10 minutes. The resulting amplification product is a single 2746 bp band on a 1% agarose gel. The entire NS3 gene was amplified using this method, however, only the NS3 protease gene is characterized herein. Second step reaction products were purified and concentrated using the Gene Clean Spin Protocol (Bio 101, Vista, Calif.). Purified products were used directly for DNA sequencing. To ensure that each HCV RNA isolation was successful, primers which cover the highly conserved 5′-untranslated (5′-UTR) region were used as a control (Yuki, N. et al. (1997) Hepatitis C virus replicative levels and efficiency of genotyping by specific PCR and antibody assay. J Clin Microbiol 35:1184-1189). PCR products from this control region were also purified as set forth above and sequenced. Sequence data from the 5′UTR region were then used to genotype each HCV strain (O'Brien, C. B. et al. D (1997) cDNA sequencing of the 5′ noncoding region (5′ NCR) to determine hepatitis C genotypes in patients with chronic hepatitis C. Digestive Diseases and Sciences 42:1087-1093). If the second round PCR amplification was unsuccessful, a new round of amplification using a second set of internal ‘backup’ primers was performed. The 5′ backup primer set forth as SEQ ID NO:64 and the 3′ backup primer set forth as SEQ ID NO:6 result in a 2377 bp amplification product, which truncates the NS3 gene (helicase region) by 19 bp.

DNA Sequencing

Sequencing of purified second step PCR reaction products was performed using the ABI Big Dye Terminator technology (Applied Biosystems, Foster City, Calif.). Five primers set forth as SEQ ID NOS:7-11 (see Table 1G, “Sequencing” subsection) designed to cover the NS3 protease region on both the sense and anti-sense strands were used. For ABI analysis, sequence reactions were run in microtiter plates using a thermocycler for 25 cycles of 96° C. for 10 seconds; 50° C. for 5 seconds; and 60° C. for 4 minutes. Reaction products were NaOAc/ETOH purified, resuspended in loading buffer, denatured and run on an ABI 377 sequencer (Applied Biosystems).

Sequence Analysis

ABI sequence results were analyzed using the ABI sequence analysis software version 3.3. Individual sequences were aligned against a consensus derived from all patient sequence data and against HCV types 1a and 1b (Accession Numbers AF009606 and AJ000009) (Yanagi, M. et al. (1997) Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 94:8738-8743; and Yanagi, M. et al., (1998),. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244:161-172). The two Genbank sequences were chosen for comparison because they are available as cloned constructs for use as positive controls for subsequent protein expression assays (data not shown). Amino acids that differ from the consensus are compared and used to determine which residues are conserved or variable.

Phylogenetic Analysis

Sequences were aligned using Sequencer 3.0, and the multiple alignment was exported as a Nexus file. Parsimony analysis was run using PAUP 3.1.1 (Swofford, D. L. (1993) PAUP: Phylogenetic analysis using parsimony. 3.1 ed. Illinois Natural History Survey, Champaign, Ill.) with a heuristic search with branch swapping. For comparison, a branch and bound option was also used to search for the most parsimonious trees. A distance matrix based on Kimura Two-Parameter distances was generated using the DNADIST program of PHYLIP Version 3.573c (Felsenstein, J. (1993) PHYLIP (phylogenetic Inference Package), 3.5 p ed. Department of Genetics, University of Washington, Seattle). A two to one transition to transversion ratio was used. The distance matrix was then analyzed by Neighbor-Joining Analysis (NJ) using the NEIGHBOR program in PHYLIP. Bootstrap support analysis was executed using 1000 resamplings for both NJ and Parsimony Analyses. The multiple data sets for the NJ were generated by the SEQBOOT program and the multiple trees were determined for consensus by the CONSENSE program, both in PHYLIP. The Parsimony bootstrap was completed using the bootstrap option in PAUP.

The number of segregating sites for each population was counted from the Sequencher 3.0 generated multiple alignments. The distinction of synonymous versus non-synonymous substitutions was made based on proposed translations of the sequences. Population mutation parameter θ=2 Nμ was estimated following Watterson (Watterson, G. A. (1975) On the number of segregating sites in genetical models without recombination. Theoretical Pop Biol 7:256-276). Tests of neutrality follow McDonald and Kreitman (McDonald, J. et al. (1991) Adaptive protein evolution at adh locus in Drosophilia. Nature 351:652-654).

Homology Protein Structure Modeling

Homology protein structure modeling by satisfaction of spatial restraints was performed according to the method of Sali, et al., 1995 (Sali, A. (1995) Comparative protein modeling by satisfaction of spatial restraints. Mol Med Today 1:270-277). Homology protein structure modeling is founded on building a structural model of a protein on the basis of close similarity to a template protein of known structure.

In the first stage of protein structure modeling, the alignment between the unknown sequence and related template structures were obtained. Secondly, restraints on various distances, angles, and dihedral angles in the sequence were derived based on its alignment with the template structures. Finally, the three dimensional models were obtained by minimizing violations of homology-derived and energy restraints, using conjugate gradients and molecular dynamics procedures. An important step in homology protein modeling experiments is the evaluation of the model quality. To ensure the quality, internal consistency checks as implemented in the software package MODELLER 4 (Sali, A. et al. (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815) were used to test the three-dimensional profile.

The comparative protein modeling software package MODELLER was used to calculate the structures of the HCV NS3/NS4 complex. This software package has been tested extensively in structural genomics projects by Sanchez and Sali, 1998 (Sanchez, R. et al. (1998) Large-scale protein structure modeling of the Saccharomyces cerevisiae genome. Proc Natl Acad Sci USA 95:13597-13602). The 2.2Å crystal structure of the complex of the HCV NS3 protease and NS4A peptide (Yan, Y. et al. 1998, supra) was used as a template for the homology modeling experiments to examine structural changes in the HCV NS3 protease clinical strains. The crystal structure of the HCV NS3/NS4A complex and the modeled structures of the HCV NS3/NS4A proteases were least-squares superimposed using the program suite O (Jones, T. A. et al. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryst A47:110-11932.

Optimization of the HCV NS3/NS4A models was carried out using default settings in MODELLER 4.0 (number of iterations in optimization=200; non-bonded restraint type=dynamic soft-sphere repulsion terms). The model is obtained by optimizing an objective function (combined spatial restraints and CHARMM energy terms enforcing proper stereochemistry) in Cartesian space.

Nucleotide Sequence GenBank Accession Numbers

The nucleotide sequences described herein have been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, on Apr. 9, 2001 and assigned Accession Numbers AF369214 through AF369263. These deposits will be maintained under the terms of the Budapest Treaty on the Intemational Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

RESULTS

Patient Population

Serum from thirty patients infected with HCV subtypes 1a or 1b was analyzed. Eighteen men and twelve women with a mean age of 50.2 years (range, 21-76) were included. Nineteen were treatment-naïve, while the remaining 11 had treatment with either α-IFN alone (patients 11, 183 and 205), α-IFN+ribavirin (pt. 176) or an initial course of α-IFN followed by a second round of combination therapy (patients 252, 174, 186, 1D, 1Y, 179, 25). All patients received 3 million units, 3× a week for 12 months except patients 11 and 205, who received a second course of α-IFN therapy of 5 million units 4× a week, and 1.5 million units 3× a week, respectively, and patients 186 and 1Y, who had therapy stopped after 6 months. No one had a sustained response. All patients had HCV RNA viral loads of between 5.1×10⁴ and 2.3×10⁶ copies/ml as determined by using the Roche Amplicor® HCV Monitor Test.

Genotyping

The conserved 5′ untranslated region was sequenced to place each strain into the respective genotype using the method of O'Brien et al. (O'Brien, C. B. et al. (1997) cDNA sequencing of the 5′ noncoding region (5′ NCR) to determine hepatitis C genotypes in patients with chronic hepatitis C. Digestive Diseases and Sciences 42:1087-1093). Genotype results showed that 21 sequences were HCV subtype 1a and 9 were subtype 1b. These data are consistent with the patient population, with HCV subtypes 1a and 1b being the most prevalent in this region of the world. The data set forth herein demonstrates a correlation between the 5′-UTR genotype and NS3 sequence data.

Amplification and Sequencing the NS3 Region from Clinical Strains

The NS3 protease gene has been successfully sequenced and amplified herein from the sera of 30 patients infected with HCV subtypes 1a or 1b. The amplification product produced a clean band with a success rate of >80% (FIG. 1). The resulting sequences were then translated and a consensus sequence was derived from the alignment of all patient sequences. Each patient sequence was compared to the consensus sequence and against the prototype sequences found in Genbank for each subtype (Genbank # AF009606 & # AJ000009) (Yanagi, M. et al., 1998, supra; see also Yanagi, M. et al., 1998, supra). The variable and conserved regions within these sequences were then determined for both nucleotide and amino acid residues.

Analysis of Nucleotide Sequence

There are 543 nucleotides that encode the NS3 protease gene. Sequence data was analyzed to determine the nucleotide distribution at each position when compared to the patient derived consensus sequence and the two prototype sequences from Genbank. For those strains belonging to HCV subtype 1a, 164 positions contained one or more nucleotide substitutions when compared to the patient consensus sequence, resulting in an overall sequence variation of 30.2% (data not shown). These included 133 transitions, 9 transversions and 22 sites with both transitions and tranversions. When compared to the prototype 1a, 20 positions were different (overall sequence variation of 3.5%), with 17 positions containing transitions and 3 containing transversions (Table 2A). There were no detected insertions or deletions. For strains typing as HCV subtype 1b, 140 positions contained one or more substitutions when compared to the patient consensus sequence, for an overall sequence variation of 25.8%. There were 114 transitions, 8 transversions and 18 sites containing both transitions and tranversions. There were 38 positions that varied from the prototype 1b sequence (overall 7.4%), with 34 transitions and 4 transversions (Table 2B). Insertions or deletions were not detected in any sequences. Without being bound by theory, because the predicted mutation rate introduced during PCR amplification was ˜0.1%, it is believed that the data portrays an accurate representation of natural genetic sequence variation.

Analysis of Amino Acid Sequence

There are 181 amino acids that comprise the NS3 protease. The effects of nucleotide substitution on the amino acid sequence showed that most of the substitutions were silent. For the 21 patient sequences belonging to HCV subtype 1a, 22 residues or 12.2% differed from the patient strain consensus (Table 3). The prototype sequence differed from the patient consensus by 5 residues (A40T, K80Q, A91S, I153L, E176G) including one mutation not found in any patient sequences (underlined). Three sites had more than two amino acid species present (Vizmanos, J. L. et al., 1998, supra; Yanagi, M. et al. (1997) Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 94:8738-8743), and one site (residue 86) was able to tolerate 4 different residues. Including the control sequence, 9 sites had substitutions of the same amino acid type, 9 sites were able to accommodate either neutral or polar amino acids, 3 sites basic or polar, 2 sites acidic or polar, and one site acidic or neutral. Only two strains were identical to the consensus with no amino acid substitutions (K and 161).

For patient strains that typed as HCV1b, there was an overall sequence variation of 12.2%, with 22 sites different from the patient derived consensus (Table 4). The patient consensus differed from the prototype sequence by 8 residues (L13V, V48I, Q80L, L94M, T98S, A150V, I153V, V1701) including 4 sites not previously identified (underlined), bringing the total number of sites containing one or more amino acids to 26. More than two amino acid species were present in 2 sites (61 and 80), and residue 67 had up to 4 different residues (residue 86 did not contain any mutations). The same type of substitution was seen in eleven sites, 8 sites accommodated either neutral or polar amino acids, 1 site basic or polar, 2 sites basic or neutral and the remaining site had an amino acid change neutral to aromatic. Only strain 153 was identical to the consensus. For either types 1a or 1b no amino acid substitutions at the known conserved residues were found.

Selection by Interferon Therapy

The most significant differences were noticed when strains were grouped according to whether or not the host had received interferon therapy. For strains that had not been subjected to interferon therapy with or without ribaviron, the overall number of mutations per patient averaged 1.9 for type 1a strains, with 14 sites containing mutations. After interferon therapy, the number of mutations per patient averaged 2.6 with 15 sites containing different amino acids. Only 7 sites were similar both before and after therapy (Table 3). For type 1b strains, the average number of mutations per patient for strains not subjected to interferon therapy was 3.6 with 18 sites varying overall. However, after interferon therapy, while the number of mutations per patient were not significantly different (3.0), the number of sites which contained mutations in the 1b strains dropped to 10, or by 56% (Table 4) with 6 sites similar in strains with or without therapy. This suggests that the sensitive strains were eliminated during interferon therapy and these 10 remaining sites may somehow be involved in resistance of the virus to interferon.

In summary, the most frequently occurring amino acid changes are represented by hydrophobic to hydrophobic amino acid mutations followed by positively charged to neutral side chain changes. The rate of mutations from a more bulky to less bulky amino acid side chain occurs at a higher rate than vice versa. In type 1b strains, sequence diversity in the NS3 protease is significantly reduced in strains from patients who have undergone IFN therapy. This suggests that sensitive strains are eliminated during interferon therapy and those strains that remain after therapy may be less sensitive to the drug.

Phylogenetic Analysis and Molecular Evolution

Parsimony analysis using a heuristic search with branch swapping detected 141 equally parsimonious trees with 696 steps. A comparable branch and bound option detected 144 equally parsimonious trees with 696 steps. The sequences are grouped in over 95% of the trees into two clades, the HCV1a and HCV1b clades. The HCV1a clade consists of 19 strains (K, 4, 11, 12, 24, 161, 170, 174, 176, 177, 183, 186, 194, 252, 1C, 1D, 1H, 1X, and 1Y) instead of 21 as identified with genotyping. The remaining samples (1, 23, 25, 153, 179, 205, 1A, 1G, 1U, 2D, and 2F) grouped with HCV1b. These results are strongly supported in the bootstrap analysis, although hierarchical relationships within the two clades are not strongly supported (FIG. 2A). In particular, FIG. 2A depicts a consensus tree of the parsimony analysis. The branch lengths are drawn to match hierarchial groups and do not reflect the mutational steps among strains. Within the HCV1b clade, the two strains 23 and 25 are sister taxa to the remaining strains. These two samples, 23 and 25, grouped with type HCV1a by genotyping and comparison of amino acid sequences.

FIG. 2B depicts a bootstrap tree from the Neighbor-joining analysis. The Neighbor-Joining analysis produced very similar results to the parsimony analysis indicating a well-separated HCV1b clade consisting of strains 1, 1G, 153, 2D, 1A, 179, 2F, 1U, and 205 (FIG. 2B). Bootstrap support of the clades, as set forth herein, are indicated next to their appropriate branches. In addition, branch lengths are scaled to genetic distances.

Strains 23 and 25 group again as a sister lineage to the HCV1b clade. These data, along with the amino acid data, suggest their representation of a genetically differentiated third clade. Hierarchical relationships within the two major clades differ somewhat from that of the consensus Parsimony tree, but none of the differences are strongly supported in the NJ bootstrap. The HCV1b clade is supported in 100% of the bootstrap samplings. The separated 23-25 grouping is supported in 97.4% of the bootstrap samplings. Within the HCV1a lade, strains 4 and 1 are monophyletic with 84.9% support, and 11, 170, and 177 are monophyletic with 66% support.

Analysis of Evolutionary Rates

Population rates of evolution for the three lineages were estimated following (Watterson, G. A., 1975, supra). The estimators of θ (±S.D.) for HCV1a, HCV1b, and PT's 23-25 are 42.28±53.77, 49.49±61.81, and 40±40.50, respectively. Thus, there is no indication of differential rates of evolution occurring among the three lineages.

Tests of non-neutral evolution between the two major lineages HCV1a and HCV1b were executed using the method of McDonald and Kreitman (McDonald, J. et al. (1991) Adaptive protein evolution at adh locus in Drosophilia. Nature 351:652-65441). Under neutrality, the ratio of synonymous and non-synonymous segregating sites should be constant within and among populations. In comparisons of the HCV1a and HCV1b populations, the X² value is 2.30 indicating no significant deviation from neutral expectations for sequence deviation among the two populations.

Molecular Modeling

Protein homology modeling experiments of HCV NS3 protease/NS4A complex were carried out with the 2.2 Å crystal structure template of the NS3 protease and NS4A peptide of (Yan, Y. et al., 1998, supra); to examine three-dimensional changes due to sequence variation in clinical strains. The most divergent strains were selected for modeling. The focus was on subtypes A and B and, therefore, two highly divergent subtype 1A and two sequence-wise very different isolates belonging to subtype 1B were selected for these studies. Four clinical strains (252, 1G, 1H, and 1U) have been selected for modeling experiments. Two of the strains (252 and 1H) belong to subtype 1a and the other two strains (1G and 1U) belong to subtype 1b. Mutations occur most frequently in loop regions or at the termini of β-strands. Mutations also occur in the α-helices of NS3.

Homology models for the HCV1a or HCV1b consensus sequences using the crystal structure the NS3/NS4A complex of (Yan, Y. et al., 1998, supra) were computed with the program suite MODELLER. The models for the 1a and 1b consensus were superimposed for detailed analysis (see FIG. 4 in Holland-Staley, C. A., et al., 2002, supra), which indicates the largest differences between the two subtypes. Moreover, there were noticeable differences both in the active site and at other positions. There are distinguishable differences in the positions of the three residues of the catalytic triad, Asp81, His57 and Ser139. The modeling results suggest functional differences for the two subtypes.

The models from HCV clinical strains 252, 1G, 1H, and 1U which contain multiple amino acid changes were superimposed on the crystal structure of the wild type NS3/NS4A complex of Yan, Y. et al., 1998, supra. The NS3/NS4A complex of strain 1G was compared with the wild type crystal structure (see FIG. 5 in Holland-Staley, C. A., et al., 2002, supra). There are distinguishable differences in the positions of the three residues for the catalytic triad (Asp81, His57 and Ser139). Similar potential differences have been observed for strains 252, 1H and 1U (data not shown) (Holland-Staley, C. A., et al. (2002) Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 147:1385-1406), which is incorporated herein by reference.

Example 2 A Decrease in Genetic Diversity Within the NS3 Helicase Gene from Clinical Isolates of the Hepatitis C Virus Correlates with Interferon Therapy

This example describes the effects of interferon therapy (with or without ribaviron) on the NS3 helicase gene from patients infected with HCV type 1a or 1b. To do this, a nested PCR reaction was developed, which allows recovery of HCV NS3 sequence data directly from patient isolates. To analyze the effects of IFN therapy, a patient derived consensus sequence was made and used to determine the overall number of mutations in each clinical isolate. Then the sequences were grouped by whether or not the patient had IFN therapy (naive vs experienced), and analyzed the number of positions which were mutated. These mutations were also used to predict response to IFN. The results demonstrate that a significant decrease in overall sequence variability occurs in those isolates which had been subjected to IFN tharapy. Thus, the present invention provides a method to analyze the effects of IFN on the HCV NS3 gene and determine its effects on the quasispecies population.

MATERIALS AND METHODS

Patient Samples and Extraction of Viral RNA

Serum from forty three patients infected with HCV subtypes 1a or 1b was analyzed. Twenty three men and twenty women with a mean age 51.1 years (range, 21-76) were included. Twenty-nine were treatment naive, while the remaining 14 had treatment with interferon alone or combined with ribaviron. All patients had HCV RNA viral loads of between 5.1×10⁴ and 2.3×10⁶ virions/ml as determined by using the Roche Amplicor® HCV Monitor Test. HCV RNA was isolated from patient serum using the QIAamp viral RNA mini isolation kit (Qiagen Inc., Valencia, Calif.). Isolation was performed according to manufacturers directions.

RT-PCR and Amplification of Viral RNA

The Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) followed by a 2^(nd) round ‘nested’ PCR reaction was used to amplify the entire NS3 gene of HCV subtypes 1a or 1b, from clinical isolates. The RT-PCR step used the Promega Access Reverse Transcriptase PCR kit (Promega Corporation, Madison, Wis.). For this, two oligonucleotide primers flanking the gene were designed. The 5′ primer (5′-CTA CTC CTG CTC CTG CTG GCG TT-3′) anneals 693 bp before the start of the NS3 gene. The 3′ primer (5′-CTG ATG AAA TTC CAC ATG TGC TTC GCC CA-3′) anneals 338 bp downstream of NS3 and is used to initiate the RT step. This allows cDNA production followed by initial amplification of the desired region. The amplification mixture containing 25 pmol of each primer, 200 μM dNTPs, 2.5 U AMV RT-polymerase, 2.5 U Tfl DNA polymerase, 1.5 mM MgSO₄, and 20 μl of viral RNA was added to a preheated (48° C.) Perkin-Elmer 9700 thermocycler (Perkin Elmer Cetus, Foster City, Calif.). The PCR protocol consisted of an RT step at 48° C. for 45 minutes, followed by an initial denaturation at 94° C. for 2 minutes, and 35 cycles of, 94° C. for 15 seconds; 55° C. for 20 seconds; 72° C. for 2 minutes; and a final extension at 72° C. for 10 minutes.

For the second step PCR reaction, the 1^(st) round PCR product was amplified using primers, which anneal inside the previous reaction, creating a ‘nested’ amplification. The second round PCR reaction used the 5′ primer (5′-GAG CCC GTC GTC TTC TC-3′) and the 3′ primer (5′-CAC TCT TCC ATC TCA TCG AAC TCC TGG TAG AG-3′). The amplification mixture containing 25 pmol of each primer, 200 μM dNTPs, 2.5 U Taq© DNA polymerase, 1.5 mM MgSO₄, and 5 μl of 1st round product was added to a preheated (94° C.) thermocycler. Initial denaturation consisted of 10 minutes at 94° C., followed by 35 cycles of, 94° C. for 15 seconds; 55° C. for 20 seconds; 72° C. for 2 minutes and a final extension at 72° C. for 10 minutes. The resulting amplification product is a single 2219 bp band on a 1% agarose gel. The entire NS3 gene was amplified using this method, however, only the NS3 helicase gene is characterized here. Second step reaction products were purified and concentrated using the Gene Clean Spin Protocol (Bio 101, Vista, Calif.). Purified products were used directly for DNA sequencing. To ensure each HCV RNA isolation was successful, primers which cover the highly conserved 5′-untranslated (5′-UTR) region were used as a control (Yuki, 1997 #226). PCR products from this control region were also purified as above and sequenced. Sequence data from the 5′UTR region were then used to genotype each HCV isolate (O'Brien, 1997 #30). If amplification was unsuccessful, a new round of RT-PCR was performed using a second 3′ ‘backup’ primer. The 3′backup primer (5′-GCC GAC ATG CAT GYC ATG ATG TAT TT-3′) results in a 2039 bp amplification product, which truncates the NS3 gene by 20 bp.

DNA Sequencing

Sequencing of purified second step PCR reaction products was performed using ABI Big Dye Terminator technology (Applied Biosystems, Foster City, Calif.). Eleven primers (A-K) designed to cover the NS3 helicase region on both the sense and anti-sense strands were used. The sense primers are: A(5′-TCG GAC CTT TAC TTG GTC ACG AG-3′), B(5′-TAC TCC ACC TAT GGC AAG TTC CT-3′), C(5′-CAT CTC ATY TTC TGC CA-3′), D(5′-GAG TGC TAT GAC GCG GGC TGT GCT T-3′), E(5′-CCA TCG TGG GAY CAA ATG TGG AAG TGT-3′), F(5′-AAA TAC ATC ATG RCA TGC ATG TCG GC-3′). Antisense primers are: G(5′-AGG AAC TTG CCA TAG GTG GAG TA-3′), H(5′-GAG TGG CAC TCA TCA CA-3′), I(5′-TCG ACT GTC TGR GTG ACA CA-3′), J(5′-GCC GAC ATG CAT GYC ATG ATG TAT TT-3′), K(5′-CAC TCT TCC ATC TCA TCG AAC TCC TGG TAG AG-3′). For ABI analysis, sequence reactions were run in microtiter plates using a thermocycler for 25 cycles of 96° C. for 10 seconds; 50° C. for 5 seconds; and 60° C. for 4 minutes. Reaction products were NaOAc/ETOH purified, resuspended in loading buffer, denatured and run on an ABI 377 sequencer (Applied Biosystems).

Sequence Analysis

ABI sequence results were analyzed using the ABI sequence analysis software version 3.3. Individual sequences were aligned against a consensus derived from all patient sequence data and against HCV types 1a (Accession Number AF009606) and 1b (Accession Number AJ000009) deposited in Genbank (Yanagi, 1997 #227) (Yanagi, 1998 #228). The two Genbank sequences were chosen for comparison because they are available as cloned constructs for use as positive controls for subsequent protein expression assays (data not shown). Amino acids that differ from the consensus are compared and used to determine which residues are conserved or variable.

Nucleotide Sequence GenBank Accession Numbers

The nucleotide sequences described herein have been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, on Apr. 9, 2001 and assigned Accession Numbers AF369214 through AF369263. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

RESULTS

Sequence Analysis of the HCV NS3 Helicase Gene

A nested PCR reaction was used to amplify and sequence the HCV NS3 helicase gene from the sera of 43 patients infected with HCV subtypes 1a or 1b. The conserved 5′ untranslated region was used to place each isolate into the respective genotype using the method of O'Brien et al.. Genotype results show that 30 sequences were HCV subtype 1a and 13 were subtype 1b. These data are consistent for the patient population, with HCV subtypes 1a and 1b being the most prevalent in this region of the world. From the NS3 sequence data, a patient-derived consensus sequence was generated and used to determine the genetic variability of the patient isolates for both nucleotide distribution and amino acid substitution.

Within the sequences analyzed, significant variation in nucleotide and amino acid sequence was identified. There are 1350 nucleotides which encode the NS3 helicase gene. Sequence data was analyzed to determine the nucleotide distribution at each position when compared to the patient derived consensus sequence and the two prototype sequences from Genbank (Genbank # AF009606 & # AJ000009). For those isolates belonging to HCV subtype 1a, 436 positions contained one or more nucleotide substitutions when compared to the patient consensus sequence, resulting in an overall sequence variation of 32.30%. These included 355 (26.30%) transitions, 30 (2.22%) transversions and 51 (3.78%) with both transitions and tranversions. The HCV1a prototype differed at 34 positions (overall sequence variation of 2.52%), with 30 positions containing transitions and 4 containing transversions. No insertions or deletions were detected in either the patient sequences or the prototype. For isolates typing as HCV subtype 1b, 390 positions contained one or more substitutions when compared to the patient consensus sequence, for an overall sequence variation of 28.89%. There were 309 (22.89%) transitions, 36 (2.67%) transversions and 45 (3.33%) containing both transitions and tranversions. There were 55 positions in the HCV 1b prototype sequence that were different than the patient-derived consensus, with an overall sequence difference of 4.07%, with 47 transitions and 8 transversions. Insertions or deletions were not detected in any sequences. Since the predicted mutation rate introduced during PCR amplification is ˜0.1%, it is believed that the data presented herein portrays an accurate representation of natural genetic sequence variation.

There are 450 amino acids that comprise the NS3 protease. The effects of nucleotide substitution on the amino acid sequence showed that most of the substitutions were silent. For the 30 patient sequences belonging to HCV subtype 1a, 65 residues or 14.44% differed from the patient-derived consensus (Table 5A). The published sequence differed from the patient consensus by 5 residues. Most sites had a single species substitution, 6 sites had three amino acid species present, with 2 sites (residues 334 & 383; numbering within NS3) able to tolerate 4 different residues. Including the control sequence, 38 sites had substitutions of the same amino acid type, 20 sites were able to accommodate either neutral or polar amino acids, 2 sites basic or polar, 2 sites acidic or polar, 1 site basic or neutral, 1 site acidic or neutral, and 1 site basic, polar or neutral. Only 1 patient (pt. 186) was identical to the consensus with no amino acid substitutions. Table 5A summarizes those mutations which occur in more than one patient sequence.

For patient isolates which typed as HCV 1b, there was an overall sequence variation of 11.33% with 51 sites different from the patient derived consensus (Table 5B). The patient consensus differed from the GenBank sequence by 13 residues, including 4 new residues, bringing the total number of sites containing one or more amino acids to 55 or 12.22% sequence variation. Three amino acid species were present in 9 sites, with residue 402 able to have 5 different amino acids and residue 470 having 7 different amino acids. The same type of amino acid substitution was seen in 26 sites, while, 20 sites were able to accommodate either neutral or polar amino acids, 5 sites basic or polar, 1 site acidic or polar, 1 acidic or basic and two sites could accommodate neutral or polar or basic amino acids (Table 5B). No patients were identical to the consensus sequence.

The difference between the consensus sequences for HCV types 1a or 1b showed an overall amino acid sequence similarity of 96.4%. The conserved motifs were surprisingly similar differing by only 4 residues (259, 263, 269 & 270). No correlation could be made between mutations in HCV types 1a and 1b. Among all the sequences, amino acid substitutions at residues which are homologous in function to those of other helicases in the same family (shaded residues in the Tables 5A and 5B) were not found. However, several mutations were found within and in close proximity to the seven motifs. Most substitutions occur only in one sequence, suggesting a random substitution due to base misincorporation by RT polymerase. HCV 1a sequences showed no substitutions in motif I, 1 substitution of L2261 in motif Ia (pt. 4C), 1 substitution of S263G in the nucleic acid binding motif (pt. 4B), 1 V3291 substitution in motif III (pt's. 23, 24, 270, 1H, 1X, 3T, 1C), 2 substitutions in motif IVa; K371R (pt. 1D) and K372R (pt's 4 and 1C), and 3 substitutions in motif V; A410S (1a control), A410T (pt. 3S) and F418Y (pt's. 4, 12, 177, 194, 198, 3P, 3S, 3T, 4C, K, and 174). The first gatekeeper motif had 1 substitution, S424T (pt's 1X and K), motif VI had 5 substitutions; R458S (pt. 3S), T459S (pt. 5P), R461L (pt. 3S), K469R (pt's. 1X, 5P, 174 and 183) and P470Q (pt. 4C), and the last gatekeeper motif had 3 substitutions; D496N (pt. 38), A497T (pt. 11) and G498S (pt. 4B). Of all the mutations, the substitutions in motif IVa were the most surprising since these two lysine residues, at positions 371 and 372, have been shown to be important in stabilizing the ss nucleic acid strand. The amino acid change of lysine to arginine in both cases indicates a need for a basic amino acid at this position. Another substitution which was interesting was at position 410 in motif V. This was interesting because the prototype sequence contained a serine instead of an alanine, a serine at this position is in most published sequences, however, the sequence presented herein identified as SEQ ID NO:1 showed an alanine presence in the patient derived consensus except for one patient who had an threonine at this position (pt. 3S). Positions 229, 418 and 469 proved interesting because several patients contained these substitutions, however, the significance of these remain unknown.

Amino acid substitutions in HCV1a isolates at positions outside existing motifs showed a high prevalence of mutations in several regions. A change from isoleucine to valine at positon 248 occurred in 9 out of 30 HCV 1a patients. Surrounding residues from 240 to 252 also showed a high degree of mutation. Residue 281 could be either glycine (consensus) or arginine (7 patients). This is surprising because the transition is from a simple to a bulky side chain. Other regions which contain higher frequency of substitution was from residue 229 to 358 and 382 to 386, residues 455 to 461, residue 557 and the COOH terminus.

Motif I in HCV1b sequences had 1 substitution, K213R (pt's. 3N and 3Q), no substitutions in Ia, 3 in the nucleic acid binding motif; A263G (control), P264S (control, pt's 1A, 2D, 3N, 6A) and 1265V (pt. 3Q). Motif II had 2 substitutions; I288M (pt. 1U), and T295I (pt. 1A), motifs III and IVa did not contain any mutations, while motif V contained 2; V406A (pt. 3O) and F418Y (pt. 3Q). Both gatekeeper motifs did not contain mutations. Motif VI contained 1 at position 470. This mutation was significant in that a total of 7 amino acids were found: R470S (control and pt. 6A), R470M (pt's. 1G, 1U and 3N), R470G (pt's 179 and 3Q), R470V (pt128), R470P (pt. 3O) and R470A (pt. 1). Similarities to HCV1a were found in regions outside of the known motifs. Positions 240 to 256, 334 to 358, 382 to 386 and the COOH terminus contained ‘hot’ regions.

The Effects of IFN Treatment

The most significant differences were noticed when isolates were grouped according to whether or not the host had received interferon therapy. A significant overall decrease in sequence variability in both HCV types 1a and 1b was evident after IFN therapy with or without ribavirin. Thus, interferon plays a role in quasispecies selection.

For HCV1a isolates which had not been subjected to interferon therapy, the overall number of mutations per patient averaged 6.47 per sequence. A total of 59 different residues were affected. After interferon therapy, the number of mutations averaged 5.0 per patient with 25 sites containing different amino acids giving an overall 56.14% drop in positions mutated (Table 5A). For type 1b isolates, the average number of mutations per patient for isolates not subjected to interferon therapy was 8.9 with 53 sites varying overall. However, after interferon therapy, the number of mutations per patient was 6.33, and the number of sites which contained mutations dramatically dropped in the 1b isolates to only 16, or by 69.78% (Table 5B). This suggests that the sensitive strains were eliminated during interferon therapy and these remaining sites may somehow be involved in resistance of the virus to interferon. No differences in either type 1a or 1b were noticed for those isolates which were subjected to combination therapy with ribavirin as opposed to interferon alone, and no correlation could be made between number or positions of mutations and viral load.

All references cited herein are expressly incorporated by reference.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. TABLE 1A HCV SEQ ID NO TYPE NAME SEQUENCE 1 2539U 5′-CCTGCTTGTGGATGATG-3′ 2 5622L 5′-CTGATGAAATTCCACATGTGCTTCGCCCA-3′ 3 2727U 5′-CTACTCCTGCTCCTGCTGGCGTT-3′ 4 5442L 5′-CACTCTTCCATCTCATCGAACTCCTGGTAGAG-3′ 5 2916U 5′-GTGTGGGTYCCCCCCCTCAAC-3′ 6 5268L 5′-GCCGACATGCATGYCATGATGTATTT-3′ 7 1a 3254U 5′-GAGCCCGTCGTCTTCTC-3′ 8 and 3486U 5′-GGCCGGGACAASAACCA-3′ 9 1b 3723U 5′-TCGGACCTTTACTTGGTCACGAG-3′ 10 4240L 5′-AGGAACTTGCCWTAGGTGGAGTA-3′ 11 3753L 5′-CGCCGGCGCACCGGAATGACATC-3′ 12 4218U 5′-TACTCCACCTATGGCAAGTTCCT-3′ 13 4896U 5′-GAGTGCTATGACGCGGGCTGTGCTT-3′ 14 4284L 5′-GAGTGGCACTCATCACA-3′ 15 4509U 5′-CATCTCATYTTCTGCCA-3′ 16 4710L 5′-TCGACTGTCTGRGTGACACA-3′ 17 5145U 5′-CCATCGTGGGAYCAAATGTGGAAGTGT-3′ 18 5268U 5′-AAATACATCATGRCATGCATGTCGGC-3′ 19 5622U 5′-TGGGCGAAGCACATGTGGAATTTCATCAG-3′ 20 5993U 5′-GCCATCCTCTCTCCTGGTGCCCT-3′ 21 5790I 5′-CACCCAYCCCCCCAAKATGTT-3′ 22 3127U 5′-CCGGRGGTCATTAYGTSCAAATGG-3′ 23 5700L 5′-CGCGGGGTTTCCAGGCAG-3′

TABLE 1B HCV SEQ ID NO TYPE NAME SEQUENCE 24 HCV2aU-1 5′-GGG ACY TAC ATC TAT GAY CA-3′ 25 2a HCV2aU-2 5′-TGA TCT TCA GTC CGA TGG AGA-3′ 26 HCV2aL-1 5′-ATG CCG CTR ATG AAR TTC CAC AT-3′ 27 HCV2aL-2 5′-CTG AAY GCC ATC ATG GAR GCC A-3′

TABLE 1C HCV SEQ ID NO TYPE NAME SEQUENCE 28 HCV2bU-1 5′-CCA ATG GAG AAG AAG GTC A-3′ 29 HCV2bU-2 5′-ATG TGG AGA CAT CCT GCA-3′ 30 HCV2bL-1 5′-TTG TGG CCT GTT GTA GGA-3′ 31 HGV2bL-2 5′-GCG CAT TCT TCC ATC TCA-3′ 32 HCV2b seqU1 5′-CCG AAA CGC TGA YGT CAT-3′ 33 2b HCV2b seqU2 5′-GGA TGG AGG CTG CTC AGC-3′ 34 HCV2b seqU3 5′-AGA CCC GAC CTT TAC CAT-3′ 35 HCV2b seqU4 5′-TTA CCC GTG TGT CAA GAC CA-3′ 36 HCV2b seqL1 5′-CCA ATG ATG GAR ATG CAG-3′ 37 HCV2b seqL2 5′-CCT TTG CSC TAG CGC ATA-3′ 38 HCV2b seqL3 5′-GAG CAC TAC GCT GTC GAA-3′ 39 HCV2b seqL4 5′-TGG CTG TGG CTA GAA CCA-3′ 40 HCV2b seqL5 5′-GTA GGC CCC AAA ACC AAG-3′ 41 HCV2b seqL6 5′-GCY CTG AAC AAG CCC ACG-3′ 42 HCV2b seqL7 5′-ACA TCT GRG TGA CTG GTC-3′

TABLE 1D SEQ HCV ID NO TYPE NAME SEQUENCE 43 HCV3aU-1 5′-CCY GTA ATA TTT AGT CCC A-3′ 44 3a HCV3aU-2 5′-TGG AAA TCA AGG TCA TCA-3′ 45 HCV3aL-1 5′-GTA GCT ACT ATG GGC TCA A-3′ 46 HCV3aL-2 5′-GCT TGC TCG ATG TAC GGG-3′

TABLE 1E SEQ HCV ID NO TYPE NAME SEQUENCE 47 HCV3bU-1 5′-CCC GTC ATC TTT AGT CCT A-3′ 48 3b HCV3bU-2 5′-TGG AGA TTA AGG TTA TCA-3′ 49 HCV3bL-1 5′-GAT TGC ACT ATG GGT CGA A-3′ 50 HCV3bL-2 5′-GCT TGC TCG ATG TAA GGA-3′

TABLE 1F SEQ HCV ID NO TYPE NAME SEQUENCE 51 3486U 5′-GGC CGG GAC AAS AAC CA-3′ 52 3723U 5′-TCG GAC CTT TAC TTG GTC ACG AG-3′ 53 3753L 5′-CGC CGG CGC ACC GGA ATG ACA TC-3′ 54 4218U 5′-TAC TCC ACC TAT GGC AAG TTC CT-3′ 55 4a 4240L 5′-AGG AAC TTG CCW TAG GTG GAG TA-3′ 56 4284L 5′-GAG TGG CAC TCA TCA CA-3′ 57 4509U 5′-CAT CTC ATY TTG TGC CA-3′ 58 4710L 5′-TCG ACT GTC TGR GTG ACA CA-3′ 59 4896U 5′-GAG TGC TAT GAC GCG GGC TGT GCT T-3′ 60 5145U 5′-CCA TCG TGG GAY CAA ATG TGG AAG TGT-3′ 61 5268U 5′-AAA TAC ATG ATG RCA TGC ATG TCG GC-3′ 62 5268L 5′-GCC GAC ATG CAT GYC ATG ATG TAT TT-3′ 63 5442L 5′-CAC TCT TCC ATC TCA TCG AAC TCC TGG TAG AG-3′

TABLE 1G SEQ BASE ID NO PAIRS TYPE SEQUENCE 1 −881 bp Amplification 5′-CCTGCTTGTGGATGATG-3′ 2 2230 bp 5′-CTGATGAAATTCCACATGTGCTTCGCCCA-3′ 3 −693 bp 5′-GTACTCCTGCTCCTGCTGGCGTT-3′ 4 2053 bp 5′-CACTCTTCCATCTGATCGAACTCGTGGTAGAG-3′ 64 −504 bp 5′-GTGTGGGTTCCGGCCCTCAACGT-3′ 6 1873 bp 5′-GCCGACATGCATGYCATGATGTATTT-3′ 7 −166 bp Sequencing 5′-GAGCCCGTCGTCTTCTC-3′ 8 66 bp 5′-GGCCGGGACAASAACCA-3′ 9 303 bp 5′-TCGGACCTTTACTTGGTCACGAG-3′ 10 918 bp 5′-AGGAACTTGCCWTAGGTGGAGTA-3′ 11 355 bp 5′-CGCCGGCGCACCGGAATGACATC-3′

TABLE 2 A. NS3 Position

1a pCV-H77C GATGCACCGCTTTATGCAGA 1a consensus AGCRTGTTAACGCGCAAGAG B. NS3 Position

1b pCV-J4L6S AGTATACTGTATATCAGTAAATCACTTTTCGTCCATCT 1b consensus GCCGCGTCACGCRATTCCGGGCTGTCCCCTAYTTGCTC The nucleotide position within NS3 is indicated.

TABLE 3         10         20         30         40         50         60         70 1a Con APITAYAQQT RGLLGCIITS LTGRDKNQVE GEVQIVSTAA QTFLATCING VCWTVYHGAG TRTIASPKGP 1a ---------- ---------- ---------- ---------T ---------- ------•--- ---------- No Treatment pt. K ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 4 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 12 ---------- ---------- --------A- ---------- ---------- ------•--- ------S--- pt. 24 ---------- ---------- ---------- ---------- ---------- ------•--- ---M------ pt. 161 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 170 ---------- ---------- --------A- ---------- ---------- ------•--- ---------- pt. 177 ---------- ---------- --------A- ---------- ---------- ------•--- ---------- pt. 194 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 1C ---------- ---------- ---------- ---------T ---------- ------•--- ---------- pt. 1H ---------- ---------- ---------- ---------T ---------- ------•--- ---------- pt. 1X ------T--- ---------- ---------- ---------- ---------- ------•--- ---------- IFN Treatment pt. 11 ---------- ---------- --------A- ---------- ---------- ------•--- ---------- pt. 252 ---------- ---------- ---------- --I-V----- -S-------- ------•--- S--------- pt. 174 ---------- ---------- ------D--- ---------- ---------- ------•--- ---------- pt. 176 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 183 ---------- ---------- -----N---- ---------- ---------- ------•--- A--------- pt. 186 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 1D ---------- ---------- ---------- ---------- ---------- ------•--- ---L------ pt. 1Y ---------- ---------- ---------- ---------- ---------- ------•--- ---------- 1a amb. ------*--- ---------- -----**-*- --*-*----* -*-------- ------•--- **-*--*---         80         90        100        110        120        130 1a Con VIQMYTNVDK DLVGWPAPQG ARSLTPCTCG SSDLYLVYTH ADVIPVRRRG DSRGSLLSPR 1a ---------Q •--------- S-----•-•- ---------- ---------- ---------- No Treatment pt. K ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 4 ---------- •--------- S-----•-•- ---------- ---------- ---------- pt. 12 ---------- •--------- T-----•-•- ---------- ---------- ---------- pt. 24 ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 161 ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 170 ---------- •--------- T-----•-•- ---------- ---------- ---------- pt. 177 ---------- •--------- T-----•-•- ---------- ---------- ---------- pt. 194 ---------Q •--------- ------•-•- ---------- ---------- ---------- pt. 1C ---------- •--------- ------•-•- ---------- ---------- ----G----- pt. 1H ---------- •--------- T-----•A•- ---------- --------Q- ---------- pt. 1X ---------- •--------- ------•-•- ---------- --------Q- ---------- IFN Treatment pt. 11 ---------- •--------- T-----•-•- ---------- ---------- ---------- pt. 252 ---------- •--------- S-----•-•- ---------- ---------- ---------- pt. 174 ---------- •--------- S-----•-•- ---------- ---------- ---------- pt. 176 ---------Q •--------- ------•-•- ---------- ---------- ---------- pt. 183 ---------- •----L---- ------•-•- ---------- ---------- ---------- pt. 186 ---------- •--------- ------•-•- ---------- --------Q- ---------- pt. 1D I--------- •----S---- ------•-•- ---------- ---------- ---------- pt. 1Y ---------- •--------- S-----•-•- ---------- ---------- ---------- 1a amb. *--------* •----*---- *-----•*•- ---------- --------*- ----*-----        140        150        160        170        180 1a Con PISYLKGSSG GPLLGPAGHA VGIFRAAVCT RGVAKAYDFI PVENLETTMR S 1a --------•- ----•---•- --L------- ---------- -----G---- - No Treatment pt. K --------•- ----•---•- ---------- ---------- ---------- - pt. 4 --------•- ----•---•- ---------- ---------- ---------- - pt. 12 --------•- ----•---•- ---------- ---------- ---------- - pt. 24 --------•- ----•---•- ---------- ---------- ---------- - pt. 161 --------•- ----•---•- ---------- ---------- ---------- - pt. 170 --------•- ----•---•- ---------- ---------- ---------- - pt. 177 --------•- ----•---•- ---------- ---------- ---------- - pt. 194 --------•- ----•---•- --L------- ---------- ---------- - pt. 1C --------•- ----•---•- ---------- ---------- ---------- - pt. 1H --------•- ----•---•- ---------- ---------- ---------- - pt. 1X -V------•- ----•---•- ---------- ---------- ---------- - IFN Treatment pt. 11 --------•- ----•---•- ---------- ---------- ---------- - pt. 252 --------•- ----•---•- ---------- ---------- ---------- - pt. 174 --------•- ----•---•- ---------- ---------- ---------- - pt. 176 --------•- ----•---•- ---------- ---------- ---------- - pt. 183 --------•- ----•---•- ---------- ---------- ---------- - pt. 186 --------•- ----•---•- ---------- ---------- ---------- - pt. 1D --------•- ----•---•- --L------- ---------- ---------- - pt. 1Y --------•- ----•---•- ---------- ---------- ---------- - 1a amb. -*------•- ----•---•- --*------- ---------- ---*-*---- -

TABLE 4         10         20         30         40         50         60         70 1b Con APITAYSQQT RGLLGCIITS LTGRSKNQVE GEVQVVSTAT QSFLATCVNG VCWTVYHGAG SKTLAGPKGP 1b ---------- --V------- ---------- ---------- -------I-- ------•--- ---------- No Treatment pt. 1 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 153 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 1A ---------- ---F------ ---------- ---------- -------I-- ------•--- C--------- pt. 1G ------A--- ---F------ ---------- ---------- -------I-- ---S--•--- ------Q--- pt. 1U ------A--- ---------- ---------- ---------- ---------- -----F•--- ------A--- pt. 2D ---------- ---------- ---------- ---------- -------I-- ------•--- T--------- pt. 2F ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 23 ---------- ---------- ---------- ---------- ---------- ------•--- -K-------- IFN Treatment pt. 179 ---------- ---------- ---------- ---------- ---------- ------•--- ---------- pt. 205 ---------- ---------- ---------- ---------- ---------- ------•--- T-----S--- pt. 25 ---------- ---------- ---------- ---------- ---------- ------•--- ---L------ 1b amb. ------*--- --**------ ---------- ---------- -------*-- ---*-*•--- **-*--*---         80         90        100        110        120        130 1b Con ITQMYTNVDQ DLVHWQAPPG ARSLTPCTCG SSDLYLVYTH ADVIPVRRRG DSRGSLLSPR 1b ---------L •--------- ---M--•S•- ---------- ---------- ---------- No Treatment pt. 1 ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 153 ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 1A ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 1G ---------- •--------- ------•-•- ---------Q ---------- ---------- pt. 1U ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 2D ---------- •-------S- ------•-•- ---------- ------C--- ---------L pt. 2F ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 23 ---------Q •--------- ------•-•- ---------- ---------- ---------- IFN Treatment pt. 179 V--------- •--------- ----I-•-•- ---------- ---------- ---------- pt. 205 ---------- •--------- ------•-•- ---------- ---------- ---------- pt. 25 ---------Q •----V---- ------•-•- ---------- ---------- ---------- 1b amb. *--------* •----*--*- ---**-•*•- ---------* ------*--- ---------*        140        150        160        170        180 1b Con PVSYLKGSSG GPLLCPSGHA VGIFRAAVCT RGVAKAVDFV PVESMETTMR S 1b --------•- ----•---•V --V------- ---------I ---------- - No Treatment pt. 1 -I------•- ----•---•V ---------- ---------- ---------- - pt. 153 --------•- ----•---•- ---------- ---------- ---------- - pt. 1A -I------•- ----•---•- ---------- ---------- ---------- - pt. 1G -I------•- ----•---•V ---------- ---------- ---------- - pt. 1U --------•- ----•---•- ---------- ---------I -------I-- - pt. 2D --------•- ----•---•- ---------- ---------- ---------- - pt. 2F -I------•- ----•---•- ---------- ---------- ---------- - pt. 23 --------•- ----•---•- ---------- ---------- ---S------ - IFN Treatment pt. 179 --------•- ----•---•- ---------- ---------- ---------- - pt. 205 -I------•- ----•---•- ---------- ---------I ---------- - pt. 25 --------•- ----•---•- ---------- ---------- ---S------ - 1b amb. -*------•- ----•---•* --*------- ---------* ---*---*-- -

TABLE 5A       190        200        210        220        230        240        250        260 +TL,64 Consensus PVFTDNSSP PAVPQSFQVA HLHAPTGSGK STKVPAAYAA QGYKVLVLNP SVAATLGFGA YMSKAHGIDP NIRTGVRTIT 1a --------- ---------- ---------- ---------- ---------- 0--------- -------V-- ---------- No Treatment pt. 4 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 12 --------- ---------- ---------- ---------- ---------- 0--------- --------E- ---------- pt. 23 --------- -----T---- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 24 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 170 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 177 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 194 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 198 --------- ---------- ---------- ---------- ---------- 0--------- -------V-- ---------- pt. 1H --------- ---------- ---------- ---------- ---------- 0--------- --------E- ---------- pt. 1X --------- ---------- ---------- ---------- ---------- 0--------- -------V-V ---------- pt. 3P --------- ---------- ---------- ---------- ---------- 0--------- -------V-- ---------- pt. 3S --------- ---------- ---------- ---------- ---------- 0--------- ---------- -V-------- pt. 3T -------T- ---------- ---------- ---------- ---------- 0--------- -------V-- ---------- pt. 4B --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 4C --------- -V-------- ---------- ---------- -----I---- 0--------- ---------- ---------- pt. 4V --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 5P --------- ---------- ---------- ---------- ---------- 0--------- ---R------ ---------- pt. 5Y --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 5Z --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- IFN Treatment pt. K --------- ---------- ---------- ---------- ---------- 0--------V -------V-- ---------- pt. 11 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 25 --------- ---------- ---------- ---------- ---------- 0--------- -------V-- ---------- pt. 161 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 174 --------- ---------- ---------- ---------- ---------- 0--------- -------V-- -L-------- pt. 176 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 183 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 186 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 252 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 1C --------- ---------- ---------- ---------- ---------- 0--------- -------V-- ---------- pt. 1D --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- 1a amb. -------*- -*---*---- ---------- ---------- -----*---- 0--------* ---*---*** -*-------- Impt. A.A. --------- ---------- ----•••••• •••------- ----•••••• •••------- ---------- ----------      Motif I      Motif Ia        270        280        290        300        310        320        330        340 Consensus TGSPITYSTY GKFLADGGCS GGAYDIIICD ECHSTDATSI LGIGTVLDQA ETAGARLVVL ATATPPGSVT VPHPNIEEVA 1a --------0- ---------- ---------- ---------- ---------- ---------- ---------- -S-------- No Treatment pt. 4 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 12 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 23 --------0- ---------- ---------- ---------- ---------- ---------- --------I- ---------- pt. 24 --------0- ---------- ---------- ---------- ---------- ---------- --------I- ---------- pt. 170 --------0- ---------- ---------- ---------- ---------- ---------- --------I- ---H------ pt. 177 --------0- ---------- ---------- ---------V ---------- ---------- ---------- ---------- pt. 194 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 198 --------0- ---------- R--------- ---------- ---------- ---------- ---------- ---------- pt. 1H --------0- ---------- ---------- ---------- ---------- ---------- --------I- ---------- pt. 1X --------0- ---------- ---------- ---------- ---------- ---------- --------I- ---S------ pt. 3P --------0- ---------- R--------- ---------- ---------- ---------- ---------- -S-------- pt. 3S --------0- ---------- R--------- ---------- ---------T ---------- ---------- ---------- pt. 3T --------0- ---------- R--------- ---------- ---------- ---------- --------I- ---------- pt. 4B --G-----0- ---------- R--------- ---------- ---------- ---------- ---------- ---------- pt. 4C --------0- ---------- ---------- ---------- ---------- ---------- ---------- -A-------- pt. 4V --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 5P --------0- ------S--- R--------- ---------- ---------- ---------- ---------- ---*------ pt. 5Y --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 5Z --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- IFN Treatment pt. K --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---S------ pt. 11 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---S------ pt. 25 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 161 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 174 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 176 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------G pt. 183 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 186 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 252 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 1C --------0- ---------- ---------- ---------- ---------- --------I- ---------- ---------- pt. 1D --------0- ---------- R--------- ---------- ---------- ---------- ---------- ---------- 1a amb. --*-----0- ------*--- *--------- ---------* ---------* ---------- --------*- -*-*-----* Impt. A.A. ---••••••• •••••----- -----••••• ••••••---- ---------- -----••••• •••••••••- ---------- Nucleic Acid Binding        Motif II          Motif III        350        360        370        380        390        400        410        420 Consensus LSTTGEIPFY GKAIPLEVIK GGRHLIFCHS KKKCDELAAK LVALGINAVA YYRGLDVSVI PTSGDVVVVA TDALMTGFTG 1a ---------- ---------- ---------0 ---------- ---------- ---------- ---------S 0--------- No Treatment pt. 4 ---------- ---------- ---------0 -R------T- ---------- ---------- ---------- 0------Y-- pt. 12 ---------- ---------- ---------0 --------T- -T-------- ---------- ---------- 0------Y-- pt. 23 ---------- ---------- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 24 ---------- ---------- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 170 ---------- ---------- ---------0 ---------- ---M------ ---------- ---------- 0--------- pt. 177 ---------- ---------- ---------0 ---------- --S--V---- ---------- ---------- 0------Y-- pt. 194 ---------- ---------- ---------0 ---------- -----V---- ---------- ---------- 0------Y-- pt. 198 ---------- ---------- ---------0 ---------- --G--V---- ---------- ---------- 0------Y-- pt. 1H ---------- ---------- ---------0 ---------- --S--V---- ---------- ---------- 0--------- pt. 1X ---------- -------A-- ---------0 ------V-T- ---M-V---- ---------- ---------- 0--------- pt. 3P ---------- ---------- ---------0 ---------- ---------- ---------- ---------- 0------Y-- pt. 3S ---------- ---------- ---------0 ---------- ---------- ---------- ---------T 0------Y-- pt. 3T ---A------ ---V------ ---------0 ---------- ---------- ---------- ---------- 0------Y-- pt. 4B ---------- ---------- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 4C ------V--- ---------- ---------0 ---------- ----V----- ---------- ---------- 0------Y-- pt. 4V ---------- -------A-- ---------0 ---------- -----V---- ---------- ---------- 0--------- pt. 5P ---------- ---------- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 5Y ---------- ---------- ---------0 ---------- --G------- ---------- ---------- 0--------- pt. 5Z ---------- ---------- ---------0 ---------- -T-------- --------I- ---------- 0--------- IFN Treatment pt. K ---------- -------A-- ---------0 ---------- ---------- ---------- ---------- 0------Y-- pt. 11 ---------- ---------- ---------0 ---------- --T------- ---------- ---------- 0--------- pt. 25 ---------- -------A-- ---------0 ---------- -----V---- ---------- ---------- 0--------- pt. 161 ---------- ---------- ---------0 ---------- -----V---- ---------- ---------- 0--------- pt. 174 ---------- -------A-- ---------0 ---------- -----V---- ---------- ---------- 0------Y-- pt. 176 ---------- ---------- ---------0 ---------- ---------- ---------- -S-------- 0--------- pt. 183 ------V--- ---------- ---------0 ---------- -----V---- ---------- ---------- 0--------- pt. 186 ---------- ---------- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 252 ---------- -------A-- ---------0 ---------- --G--V---- ---------- ---------- 0--------- pt. 1C ---------- ---------- ---------0 -R-------- -----V---- ---------- -AN------- 0--------- pt. 1D ---------- -------*-- ---------0 R--------- --G--L---- ---------- ---------- 0--------- 1a amb. ---*--*--- ---*---*-- ---------0 **----*-*- -*****---- --------*- -**------* 0------*-- Impt. A.A. ---------- ---------- -----••••• ••••------ ---------- ---------- -----••••• •••••••••-         Motif IVa          Motif V        430        440        450        460        470        480        490 Consensus DFDSVIDCNT CVTQTVDFSL DPTFTIETTT LPQDAVSRTQ RRGRTGRGKP GIYRFVAPGE RPSGMFDSSV 1a ---------- ---------- ---------- ---------- ---------- ---------- ---------- No Treatment pt. 4 ---------- ---------- ---------- ---------- ---------- -------T-- ---------- pt. 12 ---------- ---------- ---------- ---------- ---------- -------T-- ---------- pt. 23 ---------- ---------- ---------- ---------- ---------- ---------- ---------I pt. 24 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 170 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 177 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 194 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 198 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 1H ---------- ---------- ---------- ---------- ---------- ---------- ---------I pt. 1X ---T------ ---------- ---------- ------C--- --------R- ---------- ---------- pt. 3P ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 3S ---------- ---------- ------D--- ----S--S-- L--------- ---------- ---------- pt. 3T ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 4B ---------- ---------- ------D--- ---------- ---------- ---------- ---------- pt. 4C ---------- ---------- ---------- ---------- ---------Q ------T--- -----L---- pt. 4V ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 5P ---------- ---------- ---------- --------S- --------R- ---------- ---------- pt. 5Y ---------- ---------- ---------- ---------- ---------- ------T--- ---------- pt. 5Z ---------- ---------- ---------- ---------- ---------- ---------- ---------- IFN Treatment pt. K ---T------ ---------- ---------- ---------- ---------- ---------- ---------- pt. 11 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 25 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 161 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 174 ---------- ---------- ---------- ---------- --------R- ------T--- ---------- pt. 176 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 183 ---------- ---------- ---------- ---------- --------R- ---------- ---------- pt. 186 ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 252 ---------- ---------- ---------- ---------- ---------- ------T--- ---------- pt. 1C ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 1D ---------- ---------- ---------- ---------- ---------- ---------- ---------- 1a amb. ---*------ ---------- ------*--- ----*-***- *-------** ------*--- -----*---* Impt. A.A. ----•••••• ••••------ ---------- ---------• •••••••••• ---------- ----------      Gatekeeper   Motif VI        500        510        520        530        540        550        560 Consensus LCECYDAGCA WYELTPAETT VRLRAYMNTP GLPVCQDHLE FWEGVFTGLT HIDAHFLSQT KQSGENLPYL 1a ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- No Treatment pt. 4 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 12 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 23 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 24 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 170 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 177 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 194 ---------- 0--------- ---------- ---------- ---------- -M-------- ------F--- pt. 198 ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 1H ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 1X ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 3P ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 3S --Q--N---- 0--------- ---------- ---------- ---------A ---------- ---------- pt. 3T ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 4B -------S-- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 4C ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 4V ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 5P ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 5Y ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 5Z ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- IFN Treatment pt. K ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 11 ------T--- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 25 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 161 ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 174 ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- pt. 176 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 183 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 186 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 252 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 1C ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 1D ---------- 0--------- ---------- ---------- ---------- ---------- ------F--- 1a amb. --*--***-- 0--------- ---------- ---------- ---------* -*-------- ------*--- Impt. A.A. ------•••• •••••----- ---------- ---------- ---------- ---------- ----------        Gatekeeper        570        580        590        600 Consensus VAYQATVCAR AQAPPPSWDQ MWKCLIRLKP TLHGPTPLLY 1a ---------- ---------- ---------- ---------- No Treatment pt. 4 ---------- ---------- ---------- ---------- pt. 12 ---------- ---------- ---------- ---------- pt. 23 ---------- ---------- -----T---- ---------- pt. 24 ---------- ---------- -----T---- ---------- pt. 170 ---------- ---------- -----T---- ---------- pt. 177 ---------- ---------- ---------- ---------- pt. 194 ---------- ---------- -----T---- ---------- pt. 198 ---------- ---------- ---------- ---------- pt. 1H ---------- ---------- ---------- ---------- pt. 1X ---------- ---------- ---------- N--------- pt. 3P ---------- ---------- ---------- ---------- pt. 3S ---------- ---------- ---------- ---------- pt. 3T ---------- ---------- ---------- ---------- pt. 4B ---------- ---------- ---------- ---------- pt. 4C --------D- ---------- ---------- ---------- pt. 4V ---------- ---------- ---------- ---------- pt. 5P I--------- ---------- ---------- ---------- pt. 5Y ---------- ---------- ---------- ---------- pt. 5Z ---------- ---------- ---------- ---------- IFN Treatment pt. K ---------- ---------- ---------- ---------- pt. 11 ---------- ---------- -----T---- ---------- pt. 25 ---------- ---------- ---------- ---------- pt. 161 ---------- ---------- -----T---- ---------- pt. 174 ---------- ---------- ---------- ---------- pt. 176 ---------- ---------- ---------- ---------- pt. 183 ---------- ---------- ---------- ---------- pt. 186 ---------- ---------- ---------- ---------- pt. 252 ---------- ---------- ---------- ---------- pt. 1C ---------- ---------- -----T---- ---------- pt. 1D ---------- ---------- -----T---- ---------- 1a amb. *-------*- ---------- -----*---- *--------- Impt. A.A. ---------- ---------- ---------- ----------        610        620        630 Consensus RLGAVQNEVT LTHPVTKYIM TCMSADLEVV T 1a ---------- ----I----- ---------- - No Treatment pt. 4 ---------- ----I----- A--------- - pt. 12 ---------- ---------- ---------- - pt. 23 ---------- ---------- ---------- - pt. 24 --------I- ----I----- ---------- - pt. 170 ---------- ---------- ---------- - pt. 177 ---------- ----I----- ---------- - pt. 194 ---------- ----I----- ---------- - pt. 198 ---------- ----I----- ---------- - pt. 1H ---------- ---------- ---------- - pt. 1X ---------- ---------- ---------- - pt. 3P ---------I ----I----- A--------- - pt. 3S ----I----- ---------- ---------- - pt. 3T ---------- ---------- ---------- - pt. 4B ---------- ----I----- ---------- - pt. 4C ---------- ----I----- ---------- - pt. 4V ---------- ---------- ---------- - pt. 5P --------I- ---------- ---------- - pt. 5Y ---------- ----I----- ---------- - pt. 5Z ---------- ----I----- ---------- - IFN Treatment pt. K ---------- ---------- A--------- - pt. 11 ---------- ----I----- ---------- - pt. 25 --------I- ---------- ---------- - pt. 161 ---------- ----I----- ---------- - pt. 174 ---------- ----I----- A--------- - pt. 176 ---------- ----I----- ---------- - pt. 183 ---------- ---------- ---------- - pt. 186 ---------- ---------- ---------- - pt. 252 ---------- ---------- ---------- - pt. 1C ---------- ---------- ---------- - pt. 1D --------I- ---------- ---------- - 1a amb. ----*---** ----*----- *--------- - Impt. A.A. ---------- ---------- ---------- -

TABLE 5B       190        200        210        220        230        240        250        260 Consensus PVFTDNSSP PAVPQTFQVA HLHAPTGSGK STKVPAAYAA QGYKVLVLNP SVAATLGFGA YMSKAHGVDP NIRTGVRTIT 1b -------T- ---------- ---------- ---------- ---------- 0--------- -------I-- ---------- No Treatment pt. 128 --------- ---------- ---------- ---------- ---------- 0--------P ---------- ---------- pt. 1A --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 1G --------- ---------- ---------- ---------- ---------- 0--------V -----Y---- ---------- pt. 1U --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 2D --------- -----S---- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 2F --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---S------ pt. 3N --------- ---------- ---------- --R------- ---------- 0--------- -------I-- ---------- pt. 3O --------- ---------- ---------- ---------- ---------- 0--------- -----Y---- S--------- pt. 3Q --------- ---------- ---------- --R------- ---------- 0--------- ---------- ---------- pt. 6A --------- ---------- ---------- ---------- ---------- 0--------- ---------- -----I---- IFN Treatment pt. B --------- ---------- ---------- ---------- ---------- 0--------- -----Y---- ---------- pt. 1 --------- ---------- ---------- ---------- ---------- 0--------- ---------- ---------- pt. 179 --------- ---------- ---------- ---------- ---------- 0--------- ---------- S--------- 1b amb. -------*- -----*---- ---------- --*------- ---------- 0--------* -----*-*-- *--*-*---- Impt. A.A. --------- ---------- ----•••••• •••------- ----•••••• •••------- ---------- ----------     Motif I     Motif Ia        270        280        290        300        310        320        330        340 Consensus TGAPITYSTY GKFLADGGCS GGAYDIIICD ECHSTDSTTI LGIGTVLDQA ETAGARLVVL ATATPPGSVT VPHPNIEEVA 1b --GS----0- ---------- ---------- ---------- ---------- ---------- ---------- --------IG No Treatment pt. 128 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 1A ---S----0- ---------- ---------- ----I-A--- --V------- ---------- ---------- ---------- pt. 1G --------0- ---------- ---------- --------S- ---------- ---------- ---------- ---S------ pt. 1U --------0- ---------- -------M-- ---------- ---------- ---------- ---------- ---------- pt. 2D ---S----0- ---------- ---------- --------S- ---------- ---------- ---------- ---------- pt. 2F --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 3N ---S----0- ---------A ---------- ---------- ---------- ---------- ---------- ---------- pt. 3O --------0- ---------- ---------- --------S- ---------- ---------- ---------- ---------- pt. 3Q ----V---0- ---------- ---------- --------S- ---------- ---------- ---------- ---------- pt. 6A ---S----0- ---------- ---------- ------A--- --V------- ---------- ---------- ---------- IFN Treatment pt. B --------0- ---------- ---------- --------S- ---------- ---------- ---------- ---------- pt. 1 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---H----A- pt. 179 --------0- ---------- ---------- ---------- ---------- ---------- ---------- ---------- 1b amb. --***---0- ---------* -------*-- ----*-*-*- --*------- ---------- ---------- ---*----** Impt. A.A. ---••••••• •••••----- -----••••• ••••••---- ---------- -----••••• •••••••••- ---------- Nucleic Acid Binding        Motif II          Motif III        350        360        370        380        390        400        410        420 Consensus LSTTGEIPFY GKAIPIETIK GGRHLIFCHS KKKCDELAAK LSGLGLNAVA YYRGLDVSVI PTSGDVVVVA TDALMTGFTG 1b ---N------ -------A-- ---------0 ---------- -T-------- ---------- -PI------- 0--------- No Treatment pt. 128 ---------- ---------- ---------0 ---------- -S-------- ---------- ---------- 0--------- pt. 1A ---------- -------A-- ---------0 --------T- ---------- ---------- ---------- 0--------- pt. 1G ---------- -------A-- ---------0 ---------- ---------- ---------- -V-------- 0--------- pt. 1U ---------- ---------- ---------0 ---------- ---------- ---------- -A-------- 0--------- pt. 2D ---------- -------A-- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 2F ---------- ---------- ---------0 ---------- --S------- ---------- -S-------- 0--------- pt. 3N ---I------ -----L-V-- ---------0 ---------- --S--I---- ---------- ---------- 0--------- pt. 3O ---------- ---------- ---------0 ---------- -R---I---- ---------- -----A---- 0--------- pt. 3Q ---I------ -------V-- ---------0 ---------- -----I---- ---------- ---------- 0------Y-- pt. 6A ---I------ ---------- ---------0 ---------- -----F---- ---------- -S-------- 0--------- IFN Treatment pt. B ---I------ ---------- ---------0 ---------- -----I---- ---------- ---------- 0--------- pt. 1 ---I------ ---------- ---------0 ---------- ---------- ---------- ---------- 0--------- pt. 179 ---------- -------A-- ---------0 ---------- ---------- ---------- ---------- 0--------- 1b amb. ---*------ -----*-*-- ---------0 --------*- -**--*---- ---------- -**-*----- 0------*-- Impt. A.A. ---------- ---------- -----••••• ••••------ ---------- ---------- -----••••• •••••••••-         Motif IVa          Motif V        430        440        450        460        470        480        490 Consensus DFDSVIDCNT CVTQTVDFSL DPTFTIETTT VPQDAVSRSQ RRGRTGRGRR GIYRFVTPGE RPSGMFDSSV 1b ---------- ---------- ---------- ---------- ---------S ---------- ---------- No Treatment pt. 128 ---------- ---------- ---------- ---------- ---------V -T-------- ---------- pt. 1A ---------- ---------- ---------- ---------- ---------- -----A---- ---------- pt. 1G ---------- ---------- ---------- ---------- ---------M ---------- ---------- pt. 1U ---------- ---------- ---------- ---------- ---------M ---------- ---------- pt. 2D ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 2F ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 3N ---------- ---------- ---------- ---------- ---------M ---------- ---------- pt. 3O ---------- ---------- ---------- ---------- ---------P --------R- ---------- pt. 3Q ---------- ---------- ---------- ---------- ---------G ---------- ---------- pt. 6A ---------- ---------- ---------- ---------- ---------S ---------- ---------- IFN Treatment pt. B ---------- ---------- ---------- ---------- ---------- ---------- ---------- pt. 1 ---------- ---------- ---------- ---------- ---------A ---------- ---------- pt. 179 ---------- ---------- ---------- ---------- ---------G ---------- ---------- 1b amb. ---------- ---------- ---------- ---------- ---------* -*---*--*- ---------- Impt. A.A. ----•••••• ••••------ ---------- ---------• •••••••••• ---------- ----------       Gatekeeper   Motif VI        500        510        520        530        540        550        560 Consensus LCECYDAGCA WYELTPAETS VRLRAYLNTP GLPVCQDHLE FWESVFTGLT HIDAHFLSQT KQAGDNFPYL 1b ---------- 0--------- ---------- ---------- ---------- ---------- ---------- No Treatment pt. 128 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 1A ---------- 0--------- ---------- ---------- ---------- ---------- ----H-Y--- pt. 1G ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 1U ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 2D ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 2F ---------- 0--------- ---------- ---------- ---------- ---------- ----E----- pt. 3N ---------- 0--------- ---------- R--------- ---------- ---------- ---------- pt. 3O ---------- 0--------- ---------- R--------- ---------- -V-------- ---------- pt. 3Q ---------- 0--------- ---------- R--------- ---------S ---------- ---------- pt. 6A ---------- 0--------- ---------- ---------- ---------- ---------- ----E----- IFN Treatment pt. B ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 1 ---------- 0--------- ---------- ---------- ---------- ---------- ---------- pt. 179 ---------- 0--------T ---------- ---------- ---G------ ---------- ---------- 1b amb. ---------- 0--------* ---------- *--------- ---*-----* -*-------- ----*-*--- Impt. A.A. ------•••• •••••----- ---------- ---------- ---------- ---------- ----------       Gatekeeper        570        580        590        600 Consensus VAYQATVCAR AQAPPPSWDQ MWKCLIRLKP TLHGPTPLLY 1b ---------- ---------- ---------- ---------- No Treatment pt. 128 T--------- ---------- ---------- ---------- pt. 1A T--------- ---------E ---------- ---------- pt. 1G ---------- ---------- -----T---- ---------- pt. 1U ---------- ---------- ---------- ---------- pt. 2D T--------- ---------- ---------- ---------- pt. 2F ---------- ---------- -----T---- ---------- pt. 3N ---------- ---------- ---------- ---------- pt. 3O ---------- ---------- ---------- ---------- pt. 3Q ---------- ---------- ---------- ---------- pt. 6A ---------- ---------- ---------- ----S----- IFN Treatment pt. B ---------- ---------- -----T---- ---------- pt. 1 T--------- ---------- ---------- ---------- pt. 179 ---------- ---------- ---------- ---------- 1b amb. *--------- ---------* -----*---- ----*----- Impt. A.A. ---------- ---------- ---------- ----------        610        620        630 Consensus RLGAVQNEVT LTHPITKYIM ACMSADLEVV T 1b ---------I ---------- ---------- - No Treatment pt. 128 ---------- ---------- ---------- - pt. 1A ---------- ---------- ---------- - pt. 1G ---------N ---------- ---------- - pt. 1U -------DI- ----V----- ---------- - pt. 2D --------I- ---------- ---------- - pt. 2F ---------- ---------- ---------- - pt. 3N ---------- -------L-- ---------- - pt. 3O K-G------- ---------- T--------- - pt. 3Q ---------- ----V----- T--------- - pt. 6A ---------- ---------- ---------- - IFN Treatment pt. B ---------- ----V----- T--------- - pt. 1 --------I- ---------- T--------- - pt. 179 ---------- ---------- ---------- - 1b amb. *-*----*** ----*--*-- *--------- - Impt. A.A. ---------- ---------- ---------- - 

1. A nucleic acid molecule selected from the group consisting of SEQ ID NOS:1-64.
 2. A nucleic acid molecule having a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOS:1-64, wherein the oligonucleotide is capable of annealing to the NS3 or NS4 gene of HCV, or a portion thereof.
 3. A nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64.
 4. A nucleic acid molecule comprising a fragment of at least 8 nucleotides of a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64.
 5. A set of primers selected from the group consisting of two or more oligonucleotides of SEQ ID NOS:1-64.
 6. A vector comprising a nucleic acid molecule of claims 1-4.
 7. The nucleic acid molecule of claims 1-4, further comprising a label.
 8. The oligonucleotides of claim 5, further comprising a label.
 9. The nucleic acid molecule of claim 7, wherein the label is selected from the group consisting of a fluorescent group, digoxigenin, biotin, radioactive labels, chemiluminescent groups, enzymes, antibodies, luminescent agents, precipitating agents, and dyes.
 10. The oligonucleotides of claim 8, wherein the label is selected from the group consisting of a fluorescent group, digoxigenin biotin, radioactive labels, chemiluminescent groups, enzymes, antibodies, luminescent agents, precipitating agents, and dyes.
 11. A nucleic acid molecule encoding a promoter-primer comprising a sequence selected from the group consisting of SEQ ID NOS:1-64, and a promoter sequence at the 5′ end.
 12. An oligonucleotide for amplifying a nucleic acid sequence in a sample, wherein the sample contains a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64, or complement thereof.
 13. The oligonucleotide of claim 12, wherein the sample is from a patient infected with HCV.
 14. A kit for the detection of HCV, comprising an oligonucleotide, wherein the oligonucleotide comprises a nucleotide sequence which is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64.
 15. A kit for the detection of HCV, comprising a set of oligonucleotides, wherein the oligonucleotides comprise a nucleotide sequence which is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64.
 16. The kit of claim 14 or 15, further comprising at least one labeled oligonucleotide for detecting amplified HCV nucleic acid.
 17. The kit of claim 14 or 15, wherein said kit further comprises a component selected from the group consisting of a plurality of nucleotides and a nucleic acid polymerase.
 18. The kit of claim 17, wherein said kit further comprises at least one other component for conducting a polymerase amplification reaction.
 19. The kit of claim 18, wherein said kit comprises a thermostable DNA polymerase.
 20. The kit of claim 14 or 15, further comprising instructions for use.
 21. A method for amplifying a target nucleic acid, the method comprising: combining a target nucleic acid under conditions which allow for an amplification reaction to occur with: a) one or more nucleic acid primer sequences which are at least 80% identical to the sequences set forth as SEQ ID NOS:1-64; b) a nucleic acid polymerase; and c) a plurality of nucleotides, thereby resulting in an amplified target nucleic acid.
 22. The method of claim 21, wherein the target nucleic acid is from the HCV genome.
 23. The method of claim 22, wherein the target nucleic acid is from the NS3 or NS4 gene.
 24. The method of claim 22, wherein the target nucleic acid is from the serine protease portion of the NS3 gene.
 25. The method of claim 22, wherein the target nucleic acid is from the helicase portion of the NS3 gene.
 26. The method of claim 21, wherein said polymerase is selected from the group consisting of reverse transcriptase and thermostable DNA polymerase.
 27. The method of claim 21, wherein the amplified HCV nucleic acid is sequenced.
 28. The method of claim 27, wherein the sequence is evaluated for mutations.
 29. The method of claim 21, wherein the amplified HCV nucleic acid is cloned into a vector.
 30. The vector of claim
 29. 31. A method for specifically detecting HCV nucleic acids in a sample comprising: a) contacting said sample with one or more nucleic acid sequences which are at least 80% identical to the sequences set forth as SEQ ID NOS:1-64, under conditions such that said HCV nucleic acids can hybridize with said primers; b) reverse transcribing and amplifying said nucleic acids to obtain amplified HCV nucleic acids; and c) detecting the presence of said amplified HCV nucleic acids.
 32. The method of claim 31, wherein detecting the presence of said amplified HCV nucleic acids comprises: a) contacting said amplified HCV nucleic acids with a labeled oligonucleotide to obtain labeled HCV nucleic acids; and b) identifying said labeled nucleic acids.
 33. The method of claim 31, wherein amplifying said nucleic acids is accomplished by nucleic acid sequence based amplification (NASBA), a polymerase chain reaction (PCR), Transcription Mediated Amplification (TMA) or Ligase chain reaction.
 34. The method of claim 31, further comprising the step of sequencing the amplified HCV nucleic acids.
 35. The method of claim 34, further comprising evaluating the sequence for mutations.
 36. A method for determining whether a patient is resistant to an agent, the method comprising: a) obtaining a sample from a patient comprising DNA; b) performing amplification PCR on the DNA from the patient sample using a nucleic acid primer sequence which is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64; and c) analyzing the amplified product, thereby determining whether a patient is resistant to an agent.
 37. The method of claim 36, wherein the agent is an antiviral agent.
 38. The method of claim 36, wherein the agent is a protease inhibitor.
 39. The method of claim 36, wherein the agent is an inhibitor of the serine protease portion of the NS3 gene.
 40. The method of claim 36, wherein the agent is an inhibitor of the helicase portion of the NS3 gene.
 41. The method of claim 36, wherein the agent is alpha-interferon.
 42. The method of claim 36, wherein the agent is pegalated interferon.
 43. The method of claim 36, wherein the agent is a combination of agents.
 44. A method for determining whether an agent can or can not be used to treat an HCV patient, the method comprising the steps of: a) obtaining a sample from a patient infected with HCV; b) amplifying the patient sample using a nucleic acid primer sequence which is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-64; c) sequencing the resulting amplified HCV nucleic acid sequences; and d) identifying mutations in the amplified HCV nucleic acid sequence that correlate with resistance or sensitivity to an anti-viral agent, thereby determining whether an agent can or can not be used to treat an HCV patient.
 45. The method of claim 44, wherein the nucleic acid is a set of primers.
 46. A method for determining whether treatment with an agent should be continued in a patient infected with HCV, the method comprising: (a) obtaining two or more samples comprising DNA from a patient during the course of treatment; (b) performing the method of claim 21 on the samples; (c) sequencing the resulting amplified target nucleic acid product of claim 21; (d) identifying mutations present in the amplified product that correlate with resistance or sensitivity to an agent; and (e) continuing treatment when the mutations identified in the amplified product do not change during the course of treatment.
 47. A method for determining whether treatment with an agent should not be continued in a patient infected with HCV, the method comprising: (a) obtaining two or more samples comprising DNA from a patient during the course of treatment; (b) performing the method of claim 21 on the samples; (b) sequencing the resulting amplified target nucleic acid product of claim 21; (c) identifying mutations present in the amplified product that correlate with resistance or sensitivity to an agent; and (d) discontinuing treatment when the mutations identified in the amplified product change during the course of treatment.
 48. A method for evaluating a patient diagnosed as or suspected of having HCV to assess whether anti-viral therapy is likely to be successfuil, the method comprising: (a) obtaining a sample from the patient containing DNA, and (b) comparing the serine protease portions of the NS3 gene in the sample with a consensus subtype sequence, wherein the presence of one or more mutations is indicative of resistance to the anti-viral agent.
 49. A method for evaluating a patient diagnosed as or suspected of having HCV to assess whether anti-viral therapy is likely to be successful, the method comprising: (a) obtaining a sample from the patient containing DNA, and (b) comparing the helicase portions of NS3 gene to a consensus subtype sequence, wherein the presence of one or more mutations is indicative of resistance to the anti-viral agent.
 50. A method of assessing the efficacy of an agent for treating HCV, the method comprising comparing: a) nucleic acid sequences in a first sample obtained from a patient exposed to an agent, wherein the nucleic acid sequences are amplified products from one or more nucleic acid primer sequences which are at least 80% identical to the sequences set forth as SEQ ID NOS:1-64, and b) nucleic acid sequences in a second sample obtained from a patient who has not been exposed to an agent, wherein the nucleic acid sequences are amplified products from one or more nucleic acid primer sequences which are at least 80% identical to the sequences set forth as SEQ ID NOS:1-64, wherein an increased number of mutations in the nucleic acid sequences from the first sample, relative to the second sample, is an indication that the agent is not efficacious in treating HCV. 